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Abstract
Recurrent breast cancer is typically an incurable disease and, as such, is disproportionately responsible for
deaths from this disease. Recurrent breast cancers arise from the pool of disseminated tumor cells (DTCs)
that survive adjuvant or neoadjuvant therapy, and patients with detectable DTCs following therapy are at
substantially increased risk for recurrence. Consequently, the identification of pathways that contribute to the
survival of breast cancer cells following therapy could aid in the development of more effective therapies that
decrease the burden of residual disease and thereby reduce the risk of breast cancer recurrence. We now report
that Ceramide Kinase (Cerk) is required for mammary tumor recurrence following HER2/neu pathway
inhibition and is spontaneously up-regulated during tumor recurrence in multiple genetically engineered
mouse models for breast cancer. We find that Cerk is rapidly up-regulated in tumor cells following HER2/neu
down-regulation or treatment with adriamycin and that Cerk is required for tumor cell survival following
HER2/neu down-regulation. Consistent with our observations in mouse models, analysis of gene expression
profiles from over 2,200 patients revealed that elevated CERK expression is associated with an increased risk
of recurrence in women with breast cancer. Additionally, although CERK expression is associated with
aggressive subtypes of breast cancer, including those that are ER-negative, HER2-positive, basal-like, or high
grade, its association with poor clinical outcome is independent of these clinicopathological variables.
Together, our findings identify a functional role for Cerk in breast cancer recurrence and suggest the clinical
utility of agents targeted against this pro-survival pathway.
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ABSTRACT 
ROLE OF CERAMIDE KINASE IN BREAST CANCER PROGRESSION 
 
Ania Warczyk Payne 
Lewis Chodosh, M.D., Ph.D. 
 
Recurrent breast cancer is typically an incurable disease and, as such, is 
disproportionately responsible for deaths from this disease. Recurrent breast cancers arise from 
the pool of disseminated tumor cells (DTCs) that survive adjuvant or neoadjuvant therapy, and 
patients with detectable DTCs following therapy are at substantially increased risk for 
recurrence. Consequently, the identification of pathways that contribute to the survival of 
breast cancer cells following therapy could aid in the development of more effective therapies 
that decrease the burden of residual disease and thereby reduce the risk of breast cancer 
recurrence. We now report that Ceramide Kinase (Cerk) is required for mammary tumor 
recurrence following HER2/neu pathway inhibition and is spontaneously up-regulated during 
tumor recurrence in multiple genetically engineered mouse models for breast cancer. We find 
that Cerk is rapidly up-regulated in tumor cells following HER2/neu down-regulation or 
treatment with adriamycin and that Cerk is required for tumor cell survival following HER2/neu 
down-regulation. Consistent with our observations in mouse models, analysis of gene 
expression profiles from over 2,200 patients revealed that elevated CERK expression is 
associated with an increased risk of recurrence in women with breast cancer. Additionally, 
although CERK expression is associated with aggressive subtypes of breast cancer, including 
those that are ER-negative, HER2-positive, basal-like, or high grade, its association with poor 
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clinical outcome is independent of these clinicopathological variables. Together, our findings 
identify a functional role for Cerk in breast cancer recurrence and suggest the clinical utility of 
agents targeted against this pro-survival pathway. 
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CHAPTER 1: Breast Cancer Progression, Sphingolipids and Cerk 
Breast Cancer 
Breast cancer is the most common cancer diagnosed and the leading cause of cancer-
related death among women worldwide (1). In general, primary tumors can be effectively 
treated by the combination of surgery, radiotherapy, and adjuvant hormonal therapy, 
chemotherapy and/or treatment with targeted therapies, and this has resulted in 5-year survival 
rates for this disease that approach 90% (1). Despite this favorable short-term prognosis, 
however, many breast cancer survivors relapse with recurrent disease, sometimes up to 20 
years after their initial diagnosis and treatment. Since recurrent breast cancers can be treated, 
but not cured, the re-emergence of tumors following therapy is responsible for the majority of 
morbidity and mortality associated with this disease.  
There are many risk factors known to increase susceptibility to breast cancer. Non-
genetic risk factors include gender, age, age at menarche, age at first birth, parity, 
breastfeeding, menopause and hormonal therapy. Women are 100 times more likely to be 
diagnosed with breast cancer than men (2). Age is the second strongest risk factor for breast 
cancer, with 11.4% of breast cancers found in women younger than 45, while 66.4% of breast 
cancers are found in women age 55 or older (2). Lifestyle factors such as tobacco and alcohol 
use as well as obesity and physical inactivity can also increase risk of developing breast cancer 
(3–5). 
Genetic susceptibility is manifested as familial clustering of breast cancer; having a first-
degree relative with breast cancer doubles a woman’s risk of developing this disease (6). 
Between 5 and 10% of breast cancers are believed to originate from germline mutations, with 
the majority arising from mutations in the BRCA1 and BRCA2 genes, which can increase risk up 
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to 85% (7). Other genes whose germline mutations predispose women to breast cancer include 
TP53, PTEN, STK11, CDH1, ATM and CHEK2. 
In an attempt to predict outcome and response to therapy, breast cancers have 
historically been classified based on histology into ductal or lobular subtypes, and also based on 
expression of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu into three 
groups: ER+, HER2+ and triple-negative breast cancer (TNBC). Other prognostic factors that 
categorize patients as having high risk of relapse include positive lymph node involvement, high 
tumor grade and large tumor size (8,9). Recently, there has been a transition to a classification 
system based on differentiation state and gene expression profiling, leading to categorization 
into the following molecular subtypes: luminal A and luminal B (both subsets of ER+ tumors), 
ErbB2+ (which correlates broadly with HER2+ classification), basal and claudin-low (both subsets 
of triple-negative breast cancer), and normal-like.  
One of the most common oncogenes driving spontaneous breast cancer is human 
epidermal growth factor 2 (HER2/neu). It is genetically amplified or overexpressed in 15-20% of 
breast cancers (10). Soon after its identification, HER2/neu amplification was shown to be 
strongly predictive of poor recurrence-free survival, poor overall survival, and relapse, 
independent of other prognostic factors (11,12). HER2/neu, also known as ErbB2, is a receptor 
tyrosine kinase of the ErbB family, which also includes EGFR (HER1 or ErbB1), HER3 (ErbB3), and 
HER4 (ErbB4). All four members have an extracellular ligand-binding domain, a membrane-
spanning domain, and a cytoplasmic tyrosine-kinase domain. Under normal conditions, the 
spatial and temporal expression of ErbB ligands, which include EGF, TGF-α, neuregulins and 
other EGF-family growth factors, regulate activation of the ErbB receptors. Ligand binding to 
ErbB receptors induces the formation of homo- and heterodimers, which leads to activation of 
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the intrinsic kinase domains. HER2/neu does not have any known ligands, but is the preferred 
dimerization partner for the other three ErbB receptors, and under physiological conditions 
requires heterodimerization with another family member for activation. However, when 
HER2/neu is overexpressed, such as in HER2/neu-amplified breast cancers, it accumulates at the 
plasma membrane and becomes able to form constitutively activated homodimers. Receptor 
dimers become phosphorylated on specific tyrosine residues within the cytoplasmic tail, leading 
to activation of signaling cascades downstream. The main signaling pathways activated by ErbB 
receptors are the PI3K/AKT and the RAS/RAF/MAPK pathways. Other important ErbB signaling 
effectors are the STATs, SRC tyrosine kinase, and mTOR (13). 
 
Targeted Therapies and Resistance in Breast Cancer 
Targeted therapies against HER2/neu are now part of the standard of care for patients 
with HER2+ breast cancer, and have achieved significantly improved outcomes for these 
patients. Three targeted agents against HER2/neu are currently approved by the FDA: 
trastuzumab (Herceptin®, Genentech), pertuzumab (PerjetaTM, Genentech), and lapatinib 
(Tykerb®, GlaxoSmithKline). Trastuzumab is a humanized monoclonal antibody with an IgG1 Fc 
structure, which binds subdomain IV of the HER2/neu extracellular domain. Currently, 
trastuzumab is the only adjuvant therapy approved by the FDA for patients with HER2+ early 
breast cancer (EBC), after completion of chemotherapy (14). It is also indicated for metastatic 
breast cancer (MBC) patients in combination with paclitaxel or docetaxel after completion of a 
course of doxorubicin and cyclophosphamide, or concurrent with carboplatin and docetaxel. 
When combined with chemotherapy, trastuzumab has been shown in large clinical trials to 
significantly extend disease-free survival (DFS) and overall survival (OS) (15–17). Trastuzumab’s 
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complex mechanism of action has been the source of some debate, but is thought to include (1) 
disruption of ligand-independent heterodimerization of HER2/neu and HER3, (2) prevention of 
proteolytic cleavage of the HER2/neu extracellular domain (which generates a constitutively 
active form of the receptor), and (3) antibody-dependent cell-mediated cytotoxicity (ADCC), 
mediated by natural killer cells (18). Downstream effects of these mechanisms include reduced 
PI3K/AKT and MAPK signaling (19), enhanced nuclear import and stabilization of CDK inhibitor 
p27Kip1, reduced secretion of angiogenic factors (20), and impaired DNA damage response (21).  
Lapatinib is a small molecule competitive dual tyrosine kinase inhibitor of EGFR and 
HER2/neu. In a large clinical trial, it has demonstrated efficacy in combination with capecitabine 
in HER2+ MBC that has progressed after treatment with trastuzumab, anthracyclines and 
taxanes (22). Pertuzumab is a humanized monoclonal antibody that acts as a HER2/neu 
dimerization inhibitor, but clinical trials evaluating efficacy in MBC have not been successful to 
date.  
In patients with MBC, response to trastuzumab and lapatinib tends to be temporary. In 
EBC, although some patients treated in the adjuvant setting will demonstrate pathologic 
complete response (pCR), it is expected that a fraction will eventually relapse. This suggests that 
tumors harbor acquired mechanisms of resistance to these targeted therapies (18,23). 
Resistance to these therapies can be intrinsic or acquired, and there are many mechanisms that 
have been described. One mechanism is through mutation or truncation of the HER2/neu 
receptor itself, including the C-terminal truncation mutant p95-HER2 (24,25) and the exon 16 
truncation mutant Δ16-HER2 (23). Another common mechanism of resistance to HER2/neu 
targeted therapies is activation of parallel bypass signaling pathways. This can happen in many 
ways, including (1) activation of other receptor tyrosine kinases, specifically EGFR, HER3, HER4, 
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IGF-1R (18), or c-MET, (2) increasing HER-family ligands, including TGF-α (18), EGF, betacellulin 
or heregulin, (3) hormone receptor expression, (4) activation of intracellular kinases or 
deactivation of intracellular phosphatases, which can manifest as gain of function mutations in 
PIK3CA (p110a) (seen in approximately 25% of breast cancers (26)), AKT1, or PIK3R1 (p85a), or 
loss of function mutations in PTEN (seen in approximately 40% of breast cancers (26)), or in the 
tumor suppressor INPP4B (23). Resistance to targeted anti-HER2/neu therapies can also come in 
the form of defects in apoptosis and cell cycle control, including modifications in BIM, Survivin, 
or p27Kip1 (27,28). Lastly, resistance to trastuzumab can come in the form of ADCC Resistance, 
which is frequently attributable to polymorphisms in FcR genes (23). 
Many clinical trials are attempting to combat the widespread resistance to targeted 
therapy by utilizing various strategies. The ALTTO (Adjuvant Lapatinib and/or Trastuzumab 
Treatment Optimization) and NeoALTTO trials are evaluating combining lapatinib and 
trastuzumab for EBC (29), and have demonstrated improved rates of pCR with both targeted 
therapies used in combination. In the CLEOPATRA (Clinical Evaluation of Pertuzumab and 
Trastuzumab) trial, the addition of pertuzumab to trastuzumab and docetaxel was evaluated for 
HER2+ MBC (30,31), and it demonstrated significantly improved progression-free survival as well 
as overall survival. Other strategies to combat resistance include the conjugation of trastuzumab 
to an inhibitor of microtubule polymerization (trastuzumab-DM1), combining trastuzumab with 
an anti-VEGF antibody bevacizumab, using HSP90 antagonists (tanespimycin or restapimycin) 
(32,33), or the use of aromatase inhibitors (anastrozole or letrozole). 
Compounding the issue of resistance to targeted therapy in breast cancer patients is the 
problem of multidrug resistance (MDR) to chemotherapy. Systemic agents are active at the 
beginning of therapy in 90% of primary breast cancers but only in 50% of MBC (34). Mechanisms 
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of resistance to chemotherapy are varied and include: (1) decreased drug uptake (via decreased 
expression of transporters or defective endocytosis); (2) increased drug efflux (through ABC 
transporters, RLIP76/RALBP1, or ATP7A/B); (3) alterations in lipid metabolism (particularly 
ceramide metabolism, discussed in detail below, affecting both membrane structure and cell 
signaling); (4) activation of detoxifying systems, including extra-hepatic drug metabolism 
(expression of phase I cytochrome P450 enzymes or phase II conjugation enzymes); (5) 
activation of DNA repair mechanisms; and (6) evasion of drug-induced apoptosis (through up-
regulation of BCL2-family proteins) (35). The classic model of MDR involves drug efflux by P-
glycoprotein or Multidrug Resistance Protein 1 (MRP1), changes in topoisomerase II, or 
modifications in glutathione S-transferase activity.  
Although advances in screening and therapy have led to significant improvements in 
clinical outcome for breast cancer patients, up to 30% of them will eventually relapse with the 
appearance of recurrent tumors (36). Breast cancer relapse can occur early, with a peak at 
about 18 months post-surgery, or much later with a second peak at 60 months with a tapered 
plateau extending up to 15 years (37). Breast cancer has a particular propensity for late 
recurrence, with some relapses occurring up to 25 years after initial diagnosis and treatment 
(9,37–39). To mathematically model how recurrences can arise after such a long period of 
remission, continuous tumor growth models had to be modified to account for a period of 
dormancy (40).  
Recurrent breast cancers arise from the pool of disseminated tumor cells (DTCs), termed 
minimal residual disease, that survive therapy in their host presumably due to some intrinsic 
resistance mechanisms. DTCs can be identified in a substantial fraction of breast cancer patients 
at the time of diagnosis, even those with early stage disease (41) and predict poor disease-free 
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survival and overall survival (42–44). Nevertheless, despite the clinical importance of DTCs, the 
mechanisms that underlie their survival and their formation of recurrent tumors following 
therapy are largely unknown.  
 
Mouse Models of Breast Cancer Recurrence 
In order to dissect the mechanisms contributing to breast cancer recurrence, we have 
employed inducible transgenic mouse models of breast cancer that recapitulate critical features 
of disease progression as it occurs in patients. In this system, the doxycycline-dependent, 
mammary-specific expression of oncogenes relevant to human breast cancer, including 
HER2/neu, c-MYC, Wnt1 and Akt1, results in the formation of invasive mammary 
adenocarcinomas (45–49). Furthermore, in a manner analogous to the treatment of cancers 
with targeted therapies such as trastuzumab, mammary tumors regress to a non-palpable state 
following oncogene down-regulation induced by doxycycline withdrawal. Similar to breast 
cancer patients, however, mice bearing primary tumors that have regressed following oncogene 
down-regulation often develop recurrent tumors after a variable period of dormancy. 
Moreover, since recurrent tumors typically arise in the absence of re-expression of the initiating 
oncogene, the survival and growth of recurrent tumor cells is ostensibly driven by the activation 
of alternate escape pathways, as is commonly observed in cancer patients treated with targeted 
therapies. As such, these genetically engineered mouse models provide a platform with which to 
investigate the cellular and molecular mechanisms that contribute to tumor recurrence, thereby 
identifying essential pathways that may be amenable to therapeutic targeting. 
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Sphingolipids 
In recent years, sphingolipids have emerged as important regulators of tumor cell 
survival, as well as a number of other pathophysiological processes relevant to cancer, including 
proliferation, migration and inflammatory signaling. Sphingolipids represent 10-20% of cellular 
lipids, and have structural roles in membranes as well as cellular signaling roles that are the 
subject of intense ongoing investigation. Mammalian sphingolipids have an 18-carbon chain 
sphingoid backbone attached to a head group and are conjugated to an acyl group of varying 
carbon chain length (50). Sphingolipids are unique lipids in their use of the amino acid serine as 
the backbone to which acyl chains are attached (51). As the origin of their name suggests (the 
prefix sphingo means “Sphinx-like”, referring to the riddles posed by the Sphinx), the functions 
of sphingolipids have been enigmatic since their discovery in 1884. Today, sphingolipids retain a 
high level of complexity for three reasons: (1) there are a large number of distinct sphingolipids 
that can be generated by modifications of the sphingoid backbone, (2) most sphingolipids are 
synthesized by interconversion reactions catalyzed by enzymes maintaining cellular 
homeostasis, and (3) sphingolipid metabolism is extremely compartmentalized within different 
cellular membranes (50). A model for cellular homeostasis maintained by sphingolipid 
metabolism is known as the “sphingolipid rheostat”. Sphingolipid metabolism is in constant flux 
and regulates cellular fate by balancing pro-survival and pro-apoptotic sphingolipids (50). 
Sphingolipids have been implicated in an array of physiological and pathological 
processes. They were first characterized as having a role in membrane structure. An increase in 
sphingolipid content from the endoplasmic reticulum to the Golgi to the plasma membrane 
leads to membrane thickening, which is proposed to control vesicular trafficking and protein 
sorting through the secretory pathway, as well as the endocytic pathway (51,52). Sphingolipids 
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and cholesterol have been shown to self-associate to form dynamic, laterally segregated 
membrane microdomains or “lipid rafts” that act as platforms regulating diverse membrane 
proteins including signaling receptors (such as Fas (53)) by aggregating them, leading to 
activation and enhanced signaling (51,54). Glycosphingolipids have been implicated in cell 
adhesion, as binding between glycosphingolipids and lectins is important for the association of 
myelin with nerve fibers, the formation of nodes of Ranvier, and neutrophil adhesion to the 
endothelium (51,55). Furthermore, sphingolipids have been implicated in regulation of the cell 
cycle, cell growth and proliferation, angiogenesis, differentiation and senescence. 
Pathological roles for sphingolipids have been described in metabolic disorders, 
inflammatory diseases, cancer and sphingolipidoses (genetic defects that lead to abnormal 
metabolism of sphingolipids and their deposition in neural tissues that results in severe mental 
retardation (56)). Sphingolipids have been thoroughly investigated for their role in 
inflammation. The first evidence that sphingolipids could play a role in inflammation came from 
studies using TNFα, demonstrating it activates A-SMase, inducing ceramide production and 
activation of NF-κB (57). NF-κB is a transcription factor that regulates many genes with 
important roles in inflammation such as cytokines, chemokines, and pro-inflammatory enzymes 
such as COX-2 (58). Ceramide can also activate C/EBP transcription factors to induce expression 
of inflammatory genes such as TNF, IL-6, IL-8 and IL-1β (59). Some of the effects of ceramide in 
inflammation may, in fact, be attributable to C1P or S1P, which were poorly characterized at the 
time of the studies performed with ceramide. C1P has been demonstrated to directly activate 
cPLA2 leading to arachidonic acid release from membranes and downstream eicosanoid 
formation, specifically PGE2 (60). A coordinated response of S1P-induced COX-2 up-regulation 
with C1P-induced cPLA2 activation has recently been characterized (61). Mast cell degranulation 
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stimulates inflammatory responses by releasing pro-inflammatory factors from vesicles. C1P 
stimulates mast cell degranulation in a Ca2+-dependent manner, and may enhance fusion of 
vesicles with the plasma membrane (62). Mast cell stimulation by engagement of the high-
affinity IgE receptor FcεRI leads to activation of SphK and production of S1P. S1P in turn gets 
secreted and in an autocrine manner binds the S1P receptors expressed on mast cells, S1PR1 
and S1PR2, leading to migration and degranulation (63). Due to its role in mast cell activation, 
S1P has been implicated in airway hyperresponsiveness, allergy and asthma (64,65). 
Sphingolipids, particularly ceramide, have been shown to have an important role in 
cancer, specifically in regulation of cancer cell growth, differentiation, senescence and apoptosis 
(53). In fact, an inverse correlation has been found between levels of ceramide and the degree 
of malignant progression in patients with malignant astrocytomas (66). Ceramide metabolism 
has been implicated in cancer drug resistance, as decreased levels of endogenous ceramide 
caused by increased expression of glucosylceramide synthase (GCS) results in the development 
of a multidrug resistant (MDR) phenotype in many cancer cells (67). 
 
Ceramide 
De novo sphingolipid production begins in the endoplasmic reticulum with the synthesis 
of two main precursors: long-chain bases (LCBs) and very-long-chain fatty acids (VLCFAs) of 
various chain lengths (51). Condensation of L-serine and fatty acid-CoAs catalyzed by serine 
palmitoyltransferase (SPT) forms 3-ketosphinganine (also referred to as 3-keto-
dihydrosphingosine) (Figure 1.1). 3-ketosphinganine is reduced by 3-ketosphinganine reductase 
to sphinganine (also known as dihydrosphingosine). Sphinganine is then N-acylated by 
(dihydro)ceramide synthase to dihydroceramide. There are six distinct ceramide synthase 
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enzymes encoded by six genes, each of which has activity only against sphinganines of specific 
chain lengths (68). Together they generate upwards of 50 different molecular species of 
dihydroceramide. Dihydroceramide is desaturated by dihydroceramide desaturase (DES) to 
ceramide (53) (Figure 1.1). Ceramide is then transported by vesicular and non-vesicular means 
to the Golgi, where it is further elaborated at the headgroup position to generate a large variety 
of sphingolipids (51). Ceramide can be trafficked from the endoplasmic reticulum to the Golgi by 
vesicular transport or by ceramide transport protein (CERT) (69), a soluble protein regulated by 
sphingolipid levels that extracts ceramide from endoplasmic reticulum membranes directly and 
delivers it to the Golgi (51,70). Although some controversy still exists on this matter, ceramide 
trafficked by vesicular transport and by CERT appears to have different fates and be 
compartmentalized within the Golgi. In the Golgi, sphingomyelin synthases and a range of 
glycosylation enzymes generate diverse glycosphingolipids and sphingomyelin (ceramide 
conjugated to a phosphocholine moiety) (51). The vast majority of ceramide is converted to 
sphingomyelin (SM) (71), in which it is believed to be stored for rapid generation of ceramide by 
sphingomyelinases upon stimulation.  
Ceramide is the most basic sphingolipid, containing the requisite sphingosine backbone, 
a fatty acid side chain and a hydrogen atom as the head group (50). As such, ceramide 
represents the core structure of most cellular sphingolipids and is the key node in sphingolipid 
metabolism (51). Once incorporated into a large array of complex sphingolipids within cellular 
membranes, ceramide can be released by hydrolysis of the head group, but its range of activity 
is restricted locally due to its hydrophobic nature. As a result, different pools of ceramide are 
thought to be important for specific functions in each subcellular compartment (50). 
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Despite the many roles for sphingolipids in membrane structure and signaling, the way 
cells sense and regulate their overall levels is poorly characterized. Serine Palmitoyltransferase 
(SPT)-mediated condensation of serine with fatty acid-CoAs to generate LCBs and VLCFAs is the 
first and rate-limiting step in sphingolipid synthesis and is therefore a crucial point of regulation 
(51). In the endoplasmic reticulum, ORM proteins form an inhibitory multiprotein complex with 
SPT called the SPOTS complex (Serine Palmitoyltransferase, ORM1/2, TSC3, and SAC1) (51,72), 
without which cells accumulate toxic levels of sphingolipids. Further downstream, production of 
ceramides by ceramide synthase is also subject to tight regulation involving a complex balance 
between the six isoforms (51). In addition to transcriptional regulation, ceramide synthase 
activity was recently found to be modulated by reversible dimerization (51,73). 
Ceramide plays a central role in sphingolipid signaling, and its accumulation has been 
demonstrated to play an important role in mediating apoptosis in tumor cells in response to 
chemotherapy (74–77), radiotherapy (78–81) and, more recently, targeted therapy (82–86). In 
response to therapy and other cellular stresses, ceramide can be generated by the de novo 
pathway (described above), or more rapidly by the activity of sphingomyelinases (SMases). 
SMases hydrolyze the phosphodiester bond of sphingomyelin to liberate ceramide by cleavage 
of the phosphorylcholine head group (50). Acid sphingomyelinase (A-SMase) is present in 
lysosomes and has a pH-optimum of 5.0. Neutral sphingomyelinase (N-SMase) is typically active 
in mitochondria and activated by ROS, and has a pH-optimum of 7.4. N-SMase requires reactive 
oxygen species (ROS) for activation, linking oxidative injury to ceramide formation (53,87). Both 
isoforms of SMase can be found at the plasma membrane – A-SMase at the outer leaflet and N-
SMase at the inner leaflet. A-SMase was shown to be required for accumulation of ceramide 
following ionizing radiation (53,88). In fact, A-SMase deficiency, as seen in the lysosomal storage 
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disorder Niemann-Pick disease, results in resistance to radiation-induced apoptosis (50). 
Niemann-Pick disease also leads to excessive accumulation of sphingomyelin that can be toxic to 
cells, specifically neurons, leading to cell death. This results in severe neurological disease that 
leads to early death in most patients.  
Ceramide accumulation induced by either isoform of SMase has been implicated in the 
induction of apoptosis. Numerous studies support that ceramide is important in the apoptotic 
response of cancer cells to death inducers such as FAS/FAS ligand, TNFα, growth factor 
withdrawal, hypoxia and DNA damage (53,89). Ceramide can mediate apoptosis through the 
extrinsic and intrinsic pathways with both structural and signaling roles. Ceramide generated at 
the plasma membrane by A-SMase is incorporated into ceramide-enriched membrane platforms 
that help cluster death receptors, increasing formation of death-inducing signaling complexes 
(DISCs) and leading to induction of apoptotic signaling cascades (90,91). Ceramide can also 
induce mitochondrial outer membrane permeabilization, a hallmark of the intrinsic pathway of 
apoptotic signaling, by forming ceramide channels (92,93). 
 
Ceramide Signaling Pathways 
In addition to its structural roles in membranes, ceramide has been found to have many 
important signaling roles in response to stress stimuli, most of which result in induction of 
apoptosis, differentiation, or senescence. Which outcome is obtained depends on cell type, as 
ceramide acts preferentially on cancer cells to induce apoptosis and on non-transformed cells to 
induce cell-cycle arrest and/or senescence (53). The first signaling targets of ceramide to be 
characterized were named ceramide-activated protein phosphatases (CAPPs), and were later 
identified as PP1 and PP2A (94), whose downstream targets include RB, BCL2, c-JUN, PKCα, AKT, 
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and SR proteins (which modulate mRNA splicing) (95). Dephosphorylation of these targets by 
PP1 and PP2A leads to inhibition of pro-survival and mitogenic pathways and sensitization to 
apoptosis or cell cycle arrest. In response to TNFα, ceramide activates PP1 leading to RB 
dephosphorylation, which induces G0/G1 arrest in MOLT-4 acute lymphoblastic leukemia cells 
(96). Also through PP1, ceramide has been shown to lead to dephosphorylation and inactivation 
of CDK2, but interestingly not CDK4 (53,97). Additional studies showed that ceramide induces 
up-regulation of the CDK inhibitors p21WAF1 in Wi-38 human fibroblasts and p27KIP1 in 
nasopharyngeal carcinoma cells (53,97,98). Examination of the role of ceramide in senescence 
demonstrated that fibroblasts have increased ceramide levels when they become senescent, 
and furthermore that treatment with exogenous ceramide induces senescence (53,99). The 
mechanism of ceramide-induced senescence involves inhibition of phospholipase D, 
diacylglycerol generation, and activation of PKC, which leads to suppression of mitogenic 
pathways (53,99). 
Kinase targets of ceramide include stress-activated protein kinases (SAPKs) such as the 
jun kinases (JNKs), kinase suppressor of Ras (KSR), and the atypical protein kinase C (PKC) 
isoform, PKCζ (100). Ceramide is thought to activate SAPK signaling via PKCζ, RAC-1 or TAK-1 
(100,101). JNK signaling has been shown to be required for stress-induced ceramide 
accumulation (102), and activation of this pathway can lead to apoptosis or cell cycle arrest 
(100,101). The p38 SAPK, also activated by ceramide, phosphorylates the transcription factors 
CREB and ATF-1 (100,103). The first non-SAPK enzyme to be identified as a ceramide-activated 
protein kinase (CAPK) was KSR. KSR activates MAPK, RAF1, PKCζ, and MEKK (53,89), leading to 
pro-apoptotic signaling. Ceramide has also been shown to activate PKR, the dsRNA-dependent 
protein kinase, through RAX, the cellular PKR activator (104). Once activated, PKR 
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phosphorylates eIF2α, leading to inhibition of protein translation (105), which if sustained can 
lead to apoptosis.  
Another downstream signaling effector of ceramide is the endolysosomal aspartate 
protease cathepsin D, which is activated by ceramide generated in lysosomal membranes. 
Cathepsin D leads to BID-mediated activation of caspase-9 and caspase-3 (53,106). This connects 
lysosomal ceramide formation to the mitochondrial pathway of apoptosis.  
 
Ceramide Metabolism 
In light of the importance of ceramide in apoptosis induced by anti-neoplastic therapies 
and in resistance to therapy, ceramide metabolites have been the focus of increasing attention. 
Amongst the best-characterized metabolites of ceramide are glucosylceramide, sphingosine-1-
phosphate (S1P), sphingomyelin (SM), and ceramide-1-phosphate (C1P) (Figure 1.1) (53,107). 
Together, these metabolites decrease levels of apoptotic ceramide and exert anti-apoptotic 
functions of their own (108). 
Glucosylceramide is synthesized by glucosylceramide synthase (GCS), which catalyzes 
the transfer of a glucose molecule from UDP-glucose to the primary hydroxyl of ceramide to 
generate glucosyl β1-1 ceramide (109), the first step in glycolipid biosynthesis. Glucosylceramide 
is the precursor for 90% of glycosphingolipids; the remaining 10% come from the precursor 
galactosylceramide, which is generated by galactosylceramide synthase (Figure 1.1) (109). 
Glycosphingolipids (GSLs) represent more than 3000 molecular species that contain between 
one and eight sugars moieties. GSLs are clustered with sphingolipids and other membrane 
components to form GSL-Enriched Microdomains (GEMs) a type of lipid raft in the plasma 
membrane (69,110). As described above, GSL- and sphingolipid-containing lipid rafts modulate 
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membrane transport, signal transduction, and cell-cell interactions, modulating cell responses to 
stress and playing key roles in development of drug resistance (54,69).  
GCS has been shown to impart resistance to apoptosis to cancer cell lines in the context 
of cancer therapy in vitro (reviewed in (69)). However, it has not been shown to be explicitly 
involved in tumorigenesis or tumor progression in vivo. High GCS is the cause of drug resistance 
in more than 14 cancer cell lines of human breast, ovarian, colon, and cervical cancers, and 
leukemia (69,83). Multidrug resistant (MDR) cells selected by doxorubicin, paclitaxel, 
vinblastine, or imatinib overexpress GCS at levels 2- to 4-fold higher than drug-sensitive 
counterparts (69). Furthermore, silencing or inhibition of GCS sensitizes resistant cell lines to 
more than 20 anticancer agents including doxorubicin, paclitaxel, cisplatin, vinblastine and 
imatinib (69). Blocking ceramide glycosylation by inhibiting GCS in can result in increased levels 
of ceramide and decreased levels of GSLs, sensitizing cancer cells to chemotherapy (69). 
Treatment with exogenous ceramide using polymeric nanoparticles can overcome multidrug 
resistance, providing further evidence that GCS metabolism of ceramide inhibits apoptosis, 
underlying acquired drug resistance in these cell lines (69,111).  
GCS may have a functional role in human cancers, as levels of GCS mRNA or protein 
were found to be elevated four-fold in approximately 80% of advanced breast cancers (69,112). 
Elevated GCS expression is associated with ER-positive breast cancer, though GCS expression 
was not found to be predictive of DFS in either ER-positive or ER-negative breast cancer patients 
(113). Ceramide glycosylation by GCS is enhanced in breast cancer stem cells (BCSCs) but not in 
normal mammary epithelial cells, and is thought to be implicated in maintaining tumorous 
pluripotency of BCSCs (114).  
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Because it has been implicated in multidrug resistance in many contexts, GCS has 
become of interest as a drug target in cancer. “P-drugs”, including PPMP, PDMP, and PPPP, are a 
family of potent GCS inhibitors that are glucosylceramide mimetics containing a phenyl ring in 
place of the aliphatic portion of the sphingosine backbone (115). GCS inhibition by PPMP was 
shown to lead to failure of cleavage furrow ingression and cytokinesis due to ceramide 
accumulation, demonstrating that the balance of ceramides to glucosylceramides is crucial for 
effective cytokinesis (116).  
Recently, Genzyme Corporation developed and tested a set of ethylenedioxy-PPPP 
analogs as highly potent and selective GCS inhibitors (115). These inhibitors have been indicated 
for the treatment of type 1 Gaucher disease in what is known as substrate reduction therapy 
(SRT), but could potentially be useful in the treatment of multidrug resistant or refractory 
cancers in combination with chemotherapy. Gaucher disease is an autosomal recessive genetic 
disorder caused by an inactivating mutation in the GBA gene, which encodes the enzyme 
glucocerebrosidase. Glucocerebrosidase cleaves glucosylceramide to release a glucose molecule 
and ceramide, therefore its deficiency leads to toxic accumulation of glucosylceramide. Typical 
manifestations of Gaucher disease include anemia, thrombocytopenia, hepatosplenomegaly, 
and bone pathology. Some patients also develop pulmonary or neurologic symptoms (117). 
Genzyme Corporation’s N-octanoyl derivative of PPPP named Genz-112638 (Eliglustat tartrate) 
(118) underwent clinical trials (119), and N-butyl-deoxynojirimycin (NB-DNJ) has been 
commercialized (miglustat, Zavesca®) as SRT for type 1 Gaucher disease (120). Although the 
development of GCS inhibitors has been used mostly in the context of Gaucher disease, it still 
holds promise as a target in drug resistant cancers in combination with chemotherapy. 
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Another important and well-characterized metabolite of ceramide is S1P. S1P is 
generated by the deacylation of ceramide into sphingosine by ceramidase followed by 
phosphorylation by sphingosine kinase (SphK). S1P and SphK have been implicated in many 
cellular processes including cell growth, proliferation, survival and migration. The functions of 
S1P and SphK in cancer, including in tumorigenesis and resistance to therapy, have been 
extensively characterized and have led to development of many inhibitors of that pathway 
(reviewed in (121)). S1P has many intracellular roles, including activating NF-κB and inducing 
COX-2 expression, as well as paracrine and autocrine roles involving stimulation of G-protein 
coupled receptors (GPCRs) called S1P receptors (S1PRs). Activation of S1PRs has been implicated 
in cell motility as well as proliferation (122). S1P has been defined as a tumor-promoting lipid 
(53) implicated in cell growth, survival, apoptosis, invasion, vascular maturation, and 
angiogenesis (123). 
SphK has been defined as an oncogene, though no evidence has been found of 
mutations in cancer (121). SphK has, however, been found to be up-regulated in many cancers 
including stomach, lung, brain, colon, kidney and breast cancer and in non-Hodgkin’s lymphoma 
(121,124). Elevation of SphK1 in various cancers implies that it could be a molecule of prognostic 
value (125), and in fact, high SphK is associated with ER-negative status and predicts poor DFS in 
ER-positive breast cancer patients (126). However, SphK was not found to be predictive of OS or 
DFS in a prospective neoadjuvant chemotherapy trial (GeparDuo) (127). Animal studies have 
confirmed SphK to be pro-tumorigenic in orthotopic breast and prostate mouse tumor models 
(128,129). Additionally, S1P signaling has been implicated in the development of drug resistance 
in multiple cancer cell lines (82,130). Overexpression of SphK in breast cancer cells results in 
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increased proliferation and resistance to tamoxifen-induced growth arrest and apoptosis (131), 
and confers resistance to other anti-cancer drugs, sphingosine and TNFα (125,129,132). 
Many therapeutics against SphK are in development, including S1P-specific antibodies, 
small molecule inhibitors of SphK, and S1P receptor-directed agents (121). Safingol, a small 
molecule inhibitor of SphK, is in clinical trials in combination with Cisplatin in advanced solid 
tumors, where it was found to decrease plasma levels of S1P and prolong stable disease, 
inhibiting cancer progression (133). These findings suggest the potential utility of targeting 
ceramide metabolism, particularly SphK, in cancer therapy. 
Sphingomyelin (SM) is the most abundant sphingolipid and metabolite of ceramide 
(134), synthesized by the transfer of phosphorylcholine from phosphatidylcholine to ceramide 
by sphingomyelin synthase (SMS) (108), yielding mitogenic diacylglycerol (DAG) in the process 
(71). Cellular pools of SM are thought to act as a reservoir for rapid release of ceramide by 
SMases in response to cellular stresses (71,135,136). Production of SM occurs mostly in the 
trans-Golgi, where it forms microdomains that affect the organization of other membrane 
molecules, and helps establish compositional and functional differences between the 
endoplasmic reticulum, Golgi and plasma membranes (71,137). SM accumulates in the 
exoplasmic leaflet of the plasma membrane, where high packing density and affinity for 
cholesterol helps to create a rigid barrier to the extracellular environment. SM synthesis in the 
Golgi also creates a local pool of DAG, which recruits PKD and leads to formation of secretory 
vesicles (71,138). SMS regulates levels of pro-apoptotic ceramide and mitogenic DAG in opposite 
directions, so it may have a direct impact on proliferation and apoptosis (71,139,140). Up- or 
down-regulation of SMS activity has been linked to mitogenic and pro-apoptotic signaling in a 
variety of cell types (71,139,141,142), though the mechanisms remain unclear.   
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Ceramide Kinase 
Ceramide Kinase (Cerk), the only enzyme known to generate ceramide-1-phosphate 
(C1P), was identified in 1989 by Bajjalieh and colleagues from rat brain synaptic vesicles (143), 
and was subsequently found in human leukemia (HL-60) cells (144), where C1P was first 
described (145). Cerk was identified based on its homology with the catalytic domain of DAG-
kinase, as Cerk contains a DAG-kinase domain. Cerk introduced new subclass of the DAGK family 
distinct from sphingosine kinases (146), as it has no activity toward sphingosine. Cerk is a 60 kDa 
protein encoded by 537 amino acids in humans and 531 amino acids in mice, with the sequence 
identity between hCerk and mCerk being 84.4% (147). Due to the presence of a Pleckstrin 
Homology (PH) domain in its N-terminus between residues 8 and 124 (148), Cerk is exclusively 
membrane associated. Deletion of the PH domain has been demonstrated to ablate activity and 
localization to the Golgi and plasma membranes (149). The leucine 10 residue in the PH domain 
is essential for catalytic activity (150), and the β6-β7 loop bridging the two beta strands of the 
PH domain is essential for both localization and activity (151). Sequences outside of the PH 
domain are also required for proper localization and activity (152), and the interaction between 
the PH domain and PIP2 regulates plasma membrane targeting of Cerk as well as C1P levels 
(148). N-terminal myristolation of Cerk has been shown not to be required for localization or 
activity.  
Cerk contains a calmodulin (CaM) binding motif encompassing amino acid residues 422-
435 in its C-terminus (150). CaM binds directly to this site in a Ca2+-dependent manner (153), 
acting as Ca2+ sensor for Cerk (146). The binding of CaM to Cerk is regulated by Cerk 
phosphorylation at serine 427 (154), which is a putative PKA phosphorylation site (154). Cerk 
activity is enhanced by increases in Ca2+ levels, and association with a Ca2+/CaM complex is 
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necessary for activity (153). However, it was recently shown that Cerk activity is much more 
dependent on Mg2+ than Ca2+ (155). 
Two sites in hCerk have been found to be consistently phosphorylated – serines 340 and 
408 – though the functional consequence of these phosphorylation events is unclear, as point 
mutations did not lead to changes in subcellular localization or activity (154). The S340A mutant 
did, however, have decreased stability (154). The serine 340 site is a putative casein kinase II 
phosphorylation site (147), while the serine 408 site is a putative ERK or CDK phosphorylation 
site (146). 
Based on homology of Cerk’s kinase domain with DAGK’s kinase domain, the glycine 198 
residue was found to coordinate ATP (156). The glycine residue in DAGK’s kinase domain is 
known to be essential for catalytic activity, and mutation of glycine 198 to aspartate in Cerk was 
able to generate a kinase dead mutant (156). 
While much work remains to be done in characterizing the regulation of Cerk at the 
levels of transcription, translation, or post-translational modifications, one group did find by 
chromatin immunoprecipitation in keratinocytes that PPARβ binds the Cerk gene at a sequence 
located in first intron, leading to Cerk up-regulation and increased cell survival (157). Another 
group found a CREB binding site in Cerk’s promoter region and demonstrated that Cerk is up-
regulated in response to CREB phosphorylation (158). 
Cerk’s only known function is to phosphorylate ceramide at the C-1 position to generate 
ceramide-1-phosphate (C1P), with no production of the C-3 product (159). Although it has high 
homology to DAGK and SphK, Cerk has no activity against DAG or sphingosine (147). Cerk 
requires its substrate to have a minimum of 12-carbons in its acyl chain, and is stereospecific for 
naturally occurring D-erythro-ceramides (159). To date, it is unclear how C1P is 
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dephosphorylated, as no phosphatase has been identified, but C1P phosphatase activity has 
been reported in plasma membrane fractions of mouse liver and brain (160–162). 
Cerk is localized mostly to the trans-Golgi, but can also be found at the plasma 
membrane and in cytoplasmic vesicles (146). Cerk preferentially uses ceramide provided by 
CERT rather than by vesicular transport from the endoplasmic reticulum to the Golgi (163), 
which agrees with the observation that the major subspecies of C1P are C16:0, C18:0 and C20:0 
(163), the subspecies specifically transported by CERT (164). However, conflicting results show 
CERT knockdown does not affect C1P production (165), which may indicate the ability of Cerk to 
also use ceramide trafficked by vesicular transport.  
Cerk kinase activity is measurable in all mouse tissues, but is especially high in the testis, 
cerebellum, pancreas, and cerebrum. Northern analysis shows high Cerk mRNA expression in 
the mouse testis, heart and spleen, demonstrating a lack of correlation between mRNA and 
measurable kinase activity levels (155). 
Cerk knockout mice have been generated independently by two laboratories, both by 
homologous recombination in ES cells. The Igarashi group generated a knockout in the C57BL/6J 
background (166). They found those mice to be healthy and fertile, with no histological 
abnormalities. They did find changes in ambulation and defecation patterns due to abnormal 
emotional behavior associated with low C1P in Purkinje cells. However, surprisingly, they found 
C1P levels were not significantly different between Cerk+/+ and Cerk-/- mice in most tissues, 
which may explain the very mild phenotypes observed. 
The Bornancin Group generated their knockout mouse in the BALB/c background (167). 
This group saw a profound reduction in levels of C1P formed in macrophages, although they did 
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see significant residual C1P levels. The major phenotype observed was neutropenia, which was 
associated with significantly increased levels of ceramide in the serum of these animals. 
Each of these groups observed significant residual levels of C1P in Cerk-/- mice. This 
implies that another mechanism must exist to generate C1P in the absence of Cerk. Conflicting 
results exist about the existence of a Multi-Substrate Lipid Kinase (MuLK) (168), now known as 
Acylglycerol Kinase (AGK) (155) (accession numbers AJ278150 and AJ401619). There is a single 
report that recombinant MuLK may have activity toward ceramide, diacylglycerol and 1-
acylglycerol, but not sphingosine (168), though this has not been confirmed since the initial 
report.  
 
Ceramide-1-Phosphate 
All of the functions attributed to Cerk are believed to be carried out by its product, C1P. 
Soon after its discovery, C1P was shown to be mitogenic for fibroblasts, able to block apoptosis 
in macrophages, control phagocytosis in neutrophils, and mediate inflammatory responses 
(169). Many studies have characterized the effect of C1P on signaling by using exogenous short-
chain C1P, as long-chain C1Ps are extremely hydrophobic and cannot cross the plasma 
membrane. This has drawn criticism due to the non-physiological chain lengths of C1Ps utilized 
and their presence in extracellular space. C1P is not known to be secreted and no cell surface 
receptors have been identified to date. Keeping in mind those caveats, exogenous short chain 
C1P was shown to stimulate DNA synthesis and promote cell division in rat fibroblasts (170). 
Moreover, exogenous C1P was able to prevent apoptosis induced by macrophage-colony 
stimulating factor (M-CSF) withdrawal in bone marrow-derived macrophages (171), withdrawal 
of which is known to induce widespread apoptosis in these cells. C1P blocked DNA 
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fragmentation and stimulation the of caspase-9 and caspase-3 pathway, inhibiting apoptosis 
(171). C1P can also bind to and inhibit A-SMase directly – demonstrated by its inhibition of A-
SMase in cell homogenates –, preventing accumulation of ceramide (171), thus amplifying its 
anti-apoptotic effects.  
The first bona fide target of C1P to be described was cPLA2. C1P was shown to directly 
bind to and activate cPLA2 through its C2/CaLB domain at the plasma membrane (172). C1P 
specifically activates cPLA2 by an allosteric mechanism, and additionally lowers its dissociation 
constant from phosphatidylcholine-rich vesicles (172,173). The cPLA2-COX-2 pathway is often 
activated in inflammation and cancer pathogenesis (53,174), so Cerk has become of interest as a 
drug target for both of those pathologies (Figure 1.2).  
C1P is also a potent inhibitor of PP1 and PP2A in vitro (173), consistent with its 
mitogenic effects. The potential of C1P to exert anti-apoptotic effects by inhibiting PP1 activity 
may be due to SR proteins, which are well-characterized PP1 targets. SR proteins, named after 
their characteristic serine- and arginine-rich domains, are involved in alternative mRNA splicing 
and have known roles in cancer, including pro-apoptotic changes in splicing of caspase-9 and 
Bcl-x pre-mRNA (173,175). In addition to its allosteric activation of cPLA2, C1P-mediated 
inhibition of PP1 and PP2A may prevent dephosphorylation of cPLA2 at serines 505 and 727 
(173). Phosphorylation of both of these residues, mediated by the MAPK pathway, is required 
for arachidonic acid release from the membrane (176).  
Since the discovery that C1P can inhibit apoptosis in many contexts, it has been 
implicated in a variety of mitogenic signaling pathways. Importantly, C1P has been 
demonstrated to stimulate PI3K/AKT signaling in macrophages and in A549 lung 
adenocarcinoma cells, leading to NF-κB signaling and Bcl-xL up-regulation (177–183). The mTOR 
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/ S6 kinase pathway was shown to play a role downstream of PI3K/AKT signaling stimulated by 
C1P in bone marrow-derived macrophages (183). There have, however, been conflicting reports 
on whether C1P can activate or suppress MAPK signaling (170,178,179,182–184), implying this is 
most likely cell type and context specific. 
Subcellular localization of C1P may be important to its ability to activate specific 
signaling pathways. Ceramide-1-Phosphate Transport Protein (CPTP), or GLTPD1, traffics C1P 
between the trans-Golgi and the plasma membrane. Decreased CPTP trafficking leads to C1P-
mediated activation of cPLA2 in the Golgi, arachidonic acid release, and eicosanoid synthesis 
(185). 
Due to the increasing evidence that C1P (and thus Cerk) is implicated in inflammation, 
cell survival, and evasion of apoptosis, inhibitors of Cerk have been under development. NVP-
231 is a diamino-benzothiazole derivative, active against Cerk in the low nanomolar range. It 
was identified through the screening of over a million compounds (186). NVP-231 is a reversible 
inhibitor of Cerk competitive toward the ceramide substrate (Ki = 7.4 nM). It demonstrated no 
inhibition of SphK, DAGK or CERT. NVP-231 inhibits Cerk-dependent C1P formation but has no 
effect on proliferation and does not lead to induction of cell death. NVP-231 in combination 
with tamoxifen led to increased ceramide levels and reduced cell growth (186). Unfortunately, 
due to poor bioavailability and rapid clearance in vivo (186) it has no potential for clinical 
development, but could be a useful tool for in vitro investigation. 
Another inhibitor of Cerk is called K1. It was initially proposed to be a tetrasubstituted 
olefin isomer of the naturally occurring sphingosine kinase inhibitor F-12509A (187), but its 
structure was later revised to a dihydropyrane cyclization product of F-12509A (188). It is a non-
competitive inhibitor of Cerk, with no effect on SphK or DAGK. It was shown in culture to 
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suppress mast cell degranulation and was not cytotoxic. Its Ki was 2.2 µM, and its IC50 was 
approximately 200 µM (189). This inhibitor has never been tested in animals so it is not known 
whether it has potential for clinical development. 
 
Cerk and C1P in Cancer 
Increasing lines of evidence have implicated both Cerk and its product C1P in cancer. 
High CERK expression has been reported to be associated with poor recurrence-free survival in 
women with ER-negative breast cancer (190). CERK expression was also shown to be associated 
with aggressive subtypes of breast cancer, including ER-negative status, HER2-positive status, 
and high tumor grade (190).  
Lung tumor removal in non-small cell lung cancer (NSCLC) patients leads to significant 
down-regulation of several enzymes associated with ceramide metabolism in peripheral blood 
mononuclear cells, including Cerk (specifically in NK cells and T cells), S1P receptor 5 (S1PR5) and 
N-SMase 2, indicating that these enzymes may serve as biomarkers for lung cancer diagnosis 
(191). Furthermore, a retrospective analysis of five clinical trials was used to develop an RNAi 
screen-derived mitotic and ceramide pathway metagene that predicted response to adjuvant 
paclitaxel in triple negative breast cancer (192). The fact that enzymes involved in ceramide 
metabolism were found to predict paclitaxel sensitivity is consistent with previously presented 
evidence that overexpression of GCS promotes resistance to paclitaxel and GCS inhibition 
promotes paclitaxel sensitivity (192). 
Some evidence from cancer cell lines has also help confirm the role of Cerk in cancer. 
For example, Cerk was found to be up-regulated in the hormetic response of hepatoma cells to 
27 
 
low dose UV irradiation, and Cerk knockdown increased the susceptibility of these cells to UV-
induced apoptosis (193).  
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Thesis Objectives 
Although ceramide and its metabolites have been demonstrated to play important roles 
in cell death following therapy in vitro, whether this pathway plays a functional role in tumor 
progression or tumor recurrence has not been addressed. Moreover, despite being 
cytoprotective in tumor cell lines in vitro and predicting poor recurrence-free survival in ER-
negative breast cancer patients, a functional role for Cerk and C1P has not been established in 
tumorigenesis or tumor recurrence. The goal of this thesis was to try to define a functional role 
for Cerk in tumor progression through the following specific aims: 
 
1a. To test the effect of overexpressing Cerk on mammary tumor progression 
As Cerk had previously been shown to be cytoprotective in the context of many cellular 
stresses, we hypothesized that Cerk might play a role in tumor cell survival following oncogene 
down-regulation. To test this hypothesis, we first sought to characterize Cerk expression 
throughout tumor progression in inducible oncogene-driven mammary tumor mouse models. 
We then used Cerk overexpression in HER2/neu-driven mouse tumor cells to perform gain-of-
function experiments in vitro and in vivo, assessing specifically the ability of enforced Cerk 
expression to protect cells and tumors from apoptosis. We also sought to test whether Cerk was 
sufficient to promote tumor recurrence in an in vivo recurrence assay. 
 
1b. To determine whether CERK is a prognostic indicator in breast cancer patients 
Additionally, we interrogated human breast cancer patient datasets to determine 
whether CERK expression was predictive of outcome. Furthermore, we asked if high CERK 
expression was associated with other prognostic factors, such as ER status, PR status, HER2 
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status, tumor grade, lymph node status and tumor size. We also asked whether the association 
between CERK expression and relapse-free survival in breast cancer patients was independent 
of the association between CERK expression and these aggressive tumor subsets. 
 
2. To test the effect of Cerk knockdown on mammary tumor progression 
To complement Cerk gain-of-function experiments, we wanted to test the requirement 
for Cerk in tumor cell survival and tumor recurrence. We therefore performed loss-of-function 
experiments using two targeting short hairpin RNAs against Cerk. We also utilized the small 
molecule inhibitor of Cerk NVP-231 to try to inhibit Cerk in vitro.  
Due to difficulty maintaining Cerk knockdown in vivo, we sought to generate a 
conditional shRNA expression system that could be expressed at specific timepoints throughout 
tumor progression. Although this system was not optimized sufficiently to provide evidence of 
Cerk’s requirement for tumor recurrence, future studies will focus on optimizing this system to 
answer these questions. 
 
Additionally, future studies will need to identify specific signaling pathways that may be 
involved in mediating the effect of Cerk on tumor cell survival and tumor recurrence. Also, 
confirming whether the effects of Cerk are in fact mediated by C1P will be of utmost 
importance, and changes in C1P levels following manipulation of Cerk expression will be 
indicative of whether C1P is mediating the effects of Cerk.  
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Figure 1.1: Ceramide synthetic and metabolic pathways 
 
Adapted from Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis 
and treatment. Nat Rev Cancer. 2004;4:604–16.  
Summary of de novo synthesis of ceramide as well as major ceramide metabolic pathways. 
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Figure 1.2: C1P activates cPLA2 leading to eicosanoid synthesis and tumor-promoting signaling 
 
Based on and adapted from Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 
2010;10:181–93. 
C1P generated by Cerk activates cPLA2 at the plasma and Golgi membranes, leading to cleavage 
of arachidonic acid from membrane phospholipids. Arachidonic acid is then converted into a 
variety of eicosanoids, including prostaglandins, specifically PGE2. PGE2 is known to be pro-
tumorigenic and activate EP1-4 receptors in an autocrine and paracrine manner, leading to 
mitogenic signaling through pathways including Ras and inhibition of GSK3β.  
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Figure 1.3. Ceramide and ceramide-1-phosphate signaling pathways 
 
Overview of signaling pathways downstream of ceramide and ceramide-1-phosphate. Ceramide 
signals through many pro-apoptotic pathways, including SAPKs and the phosphatases PP1 and 
PP2A. By contributing to cell cycle arrest, protein synthesis arrest, and mitochondrial 
permeability, ceramide promotes apoptosis. In contrast, ceramide-1-phosphate signals through 
several pro-survival and inflammatory pathways including PI3K/AKT and cPLA2, which is the rate-
limiting step in eicosanoid synthesis. 
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CHAPTER 2: Gain-of-Function Cerk Experiments 
Introduction 
C1P and its synthetic enzyme Ceramide Kinase (Cerk) have been implicated in a number 
of pro-tumorigenic cellular processes, including inflammation, proliferation and cell survival. 
Several studies have shown that Cerk is cytoprotective in many contexts by generating C1P, 
which signals through the PI3K/AKT pathway (177,180,194). C1P has also been reported to 
activate cPLA2, recruiting it to Golgi and plasma membranes, resulting in the cleavage of 
arachidonic acid that is then converted into a variety of eicosanoids, including prostaglandins. 
Prostaglandins have, in turn, been associated with many inflammatory processes as well as 
regulation of cell growth (195) and cancer (reviewed in (196)). High CERK expression has been 
reported to be associated with poor recurrence-free survival in women with ER-negative breast 
cancer (190). CERK expression has also shown to be associated with aggressive subtypes of 
breast cancer, including ER-negative status, HER2-positive status, and high tumor grade (190).  
Although ceramide and its metabolites have been demonstrated to contribute to cell 
death following therapy in vitro, whether this pathway plays a functional role in tumor 
progression in vivo has not been addressed. Moreover, despite being cytoprotective in tumor 
cell lines in vitro and predicting poor recurrence-free survival in ER-negative breast cancer 
patients, functional roles for Cerk and C1P have not been established in tumorigenesis or tumor 
recurrence. 
In this study, we identify a functional role for Cerk in breast cancer recurrence. We 
demonstrate that Cerk is spontaneously up-regulated during tumor recurrence in mice and is 
rapidly up-regulated in response to HER2/neu pathway inhibition or treatment with adriamycin. 
We further establish that Cerk promotes tumor cell survival following HER2/neu down-
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regulation and is sufficient to promote mammary tumor recurrence. Consistent with 
observations in mice and with an analogous role for this enzyme in human breast cancer, we 
find that elevated CERK expression in primary tumors is strongly associated with an increased 
risk of relapse in breast cancer patients. Taken together, these observations provide the first 
functional evidence for a role for Cerk in cancer and identify a potential target for the treatment 
and prevention of breast cancer recurrence.  
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Results 
Cerk is spontaneously up-regulated in recurrent mammary tumors in mice 
As an initial approach to investigating the potential role of sphingolipid metabolites in 
tumor progression, we evaluated the expression of enzymes involved in sphingolipid 
metabolism in primary and recurrent mammary tumors induced by the inducible expression – 
and subsequent down-regulation – of HER2/neu, c-MYC, Wnt1, and Akt1 in MMTV-rtTA;TetO-
HER2/neu, MMTV-rtTA;TetO-MYC, MMTV-rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 
transgenic mice (45–49). Expression of sphingosine kinase 1, which generates S1P from 
sphingosine, and glucosylceramide synthase, which generates glucosylceramide from ceramide, 
were not consistently altered in recurrent compared to primary tumors (data not shown). In 
contrast, expression of Cerk, which generates C1P from ceramide, was markedly up-regulated in 
recurrent tumors compared to primary tumors generated by induction of each of the four 
oncogenes tested (Figure 2.1A). 
 
Cerk is up-regulated following HER2/neu pathway inhibition 
To identify the stage of tumor progression at which Cerk up-regulation occurs, tumors 
were harvested from doxycycline-induced MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice bearing 
primary tumors, MTB/TAN mice bearing primary tumors in which the HER2/neu transgene had 
been de-induced for 48 hr or 96 hr, or MTB/TAN mice bearing primary tumors that had fully 
regressed and then spontaneously recurred following doxycycline withdrawal and HER2/neu 
down-regulation. 
Quantitative RT-PCR analysis demonstrated Cerk up-regulation in mammary tumors 
within 48 hr following doxycycline withdrawal, which reached statistical significance by 96 hr 
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and remained up-regulated 4.1-fold in recurrent tumors (Figure 2.1B). To determine whether 
alterations in Cerk expression occur in tumor cells subjected to HER2/neu down-regulation, we 
next evaluated Cerk mRNA levels following oncogene down-regulation in vitro in doxycycline-
dependent primary tumor cells derived from a tumor-bearing MTB/TAN mouse. Doxycycline 
withdrawal resulted in Cerk up-regulation within 24 hr that became somewhat more 
pronounced over time (Figure 2.1C). This finding suggests that Cerk may be acutely up-regulated 
in primary tumor cells in response to HER2/neu pathway down-regulation. 
To determine whether CERK up-regulation is an evolutionarily conserved response to 
HER2/neu pathway inhibition in breast cancer cells, we treated two HER2/neu-amplified human 
breast cancer cell lines, BT474 and SKBR3, with the dual inhibitor of HER2/neu and EGFR, 
lapatinib. Treatment with lapatinib resulted in up-regulation of CERK in each of the HER2/neu 
amplified cell lines relative to controls within 24 hr (Figure 2.1D, E), demonstrating that CERK up-
regulation is conserved in human and mouse breast cancer cells following HER2/neu pathway 
inhibition. 
To determine whether CERK up-regulation is also seen in response to other types of 
anti-neoplastic therapy, we treated BT20 human breast cancer cells with the chemotherapeutic 
agent adriamycin for increasing periods of time. Adriamycin treatment resulted in marked up-
regulation of CERK within 8 hr, peaking at 6.5-fold at 24 hr relative to vehicle-treated controls 
(Figure 2.1F). Consistent with this, CERK was up-regulated within 4 hr in primary MTB/TAN 
mouse tumor cells treated with adriamycin, with levels peaking at 4.5-fold at 16 hr (Figure 2.1G). 
Together, these data indicate that CERK is rapidly up-regulated in mouse and human mammary 
tumor cells following HER2/neu pathway inhibition or treatment with adriamycin. 
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Cerk promotes tumor cell survival in vitro following HER2/neu down-regulation 
Having observed acute Cerk up-regulation following HER2/neu pathway inhibition in 
vivo and in vitro, we hypothesized that Cerk up-regulation might contribute to the survival of 
tumor cells following HER2/neu pathway inhibition. Doxycycline was removed from the culture 
media of primary MTB/TAN tumor cell lines transduced with expression constructs for wild type 
Cerk or the kinase dead mutant G198D-Cerk, which are expressed at comparable levels (data not 
shown), or a control vector. Cells were then stained for cleaved caspase-3 and Ki67. 
Cerk overexpressing MTB/TAN cells exhibited markedly reduced staining for cleaved 
caspase-3 compared to control cells following HER2/neu down-regulation induced by 
doxycycline withdrawal (Figure 2.2A, B). In contrast, MTB/TAN cells transduced with kinase dead 
G198D-Cerk exhibited an increase in cleaved caspase-3 staining following HER2/neu down-
regulation that was comparable to control cells (Figure 2.2A, B). As anticipated, proliferation 
rates as measured by Ki67 staining fell dramatically upon HER2/neu down-regulation, but did 
not differ between Cerk, G198D-Cerk, and empty vector controls (Figure 2.2C). These findings 
suggest that Cerk overexpression is sufficient to suppress apoptosis induced by HER2/neu 
pathway inhibition and that it does so in a kinase-dependent manner. 
To confirm the increase in apoptosis observed by immunofluorescence, we performed 
Western blots for cleaved caspase-3 and cleaved PARP under the same culture conditions. 
Consistent with immunofluorescence results, Cerk overexpression reduced levels of cleaved 
PARP and cleaved caspase-3 detected following doxycycline withdrawal (Figure 2.2D, E, F). 
Kinase dead G198D-Cerk had comparable levels of cleaved PARP and cleaved caspase-3 as 
controls, indicating that kinase activity is required for Cerk to protect cells from apoptosis.  
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Cerk promotes tumor cell survival in vivo following HER2/neu down-regulation 
Having observed a protective effect of Cerk overexpression in MTB/TAN cells in vitro 
upon HER2/neu down-regulation, we wanted to determine whether this would occur in vivo. To 
address this possibility, we generated mice bearing orthotopic tumors derived from MTB/TAN 
primary tumor cells overexpressing wild type Cerk, kinase dead G198D-Cerk, or a control vector. 
We then performed immunofluorescence staining for cleaved caspase-3 on histological sections 
from primary tumors on doxycycline or in which HER2/neu had been acutely down-regulated for 
48 or 96 hr.  
Primary tumors from control, Cerk and G198D-Cerk overexpressing cohorts exhibited 
comparable, low levels of cleaved caspase-3 staining in the presence of HER2/neu expression 
and a marked increase in cleaved caspase-3 staining was observed 48 hr following doxycycline 
withdrawal (Figure 2.3A, B). Strikingly, however, tumors overexpressing Cerk displayed a 
significantly blunted apoptotic response to HER2/neu down-regulation at 48 hr post-
deinduction, and cleaved caspase-3 levels remained lower in Cerk overexpressing tumors 
compared to controls at 96 hr (Figure 2.3A, B). In contrast, tumors overexpressing the kinase 
dead mutant G198D-Cerk did not blunt the apoptotic response and exhibited high levels of 
cleaved caspase-3 comparable to control tumors following HER2/neu down-regulation (Figure 
2.3A, B). These findings indicate that Cerk up-regulation protects tumor cells from apoptosis 
following HER2/neu pathway inhibition, suggesting a cellular mechanism for the observation 
that cells with Cerk knockdown are selected against following oncogene down-regulation in vivo. 
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Cerk promotes mammary tumor recurrence in vivo 
Cerk’s ability to inhibit apoptosis following HER2/neu down-regulation in tumor cells in 
vivo and in vitro, coupled with its spontaneous up-regulation in recurrent mammary tumors in 
multiple genetically engineered mouse models, suggested the possibility that Cerk might 
promote breast cancer recurrence by enhancing the survival of tumor cells following therapy. To 
test this hypothesis, we injected primary MTB/TAN tumor cells transduced with a Cerk 
expression vector or a control vector into the mammary fat pads of nu/nu mice maintained on 
doxycycline. Following primary tumor formation, mice were withdrawn from doxycycline to 
induce oncogene down-regulation and tumor regression (Figure 2.4A). All tumors regressed to a 
non-palpable state, irrespective of Cerk expression status. Mice were then monitored for tumor 
recurrence.  
Consistent with our hypothesis, Cerk expression in MTB/TAN tumor cells markedly 
accelerated tumor recurrence, with median time to recurrence decreasing from 178 days for 
control tumors to 130 days in Cerk overexpressing tumors (Figure 2.4B, HR = 4.44, p = 0.0006). 
However, mean growth rate of recurrent tumors was not found to be different between control 
and Cerk overexpressing cohorts, indicating increased rates of proliferation are unlikely to be 
responsible for the observed difference in latency to tumor recurrence (Figure 2.4C). 
The above experiment could not rule out the possibility that the increased rate of 
relapse observed for Cerk overexpressing tumors was due to effects of Cerk expression during 
primary tumor formation. That is, if Cerk expression resulted in the formation of primary tumors 
with different properties than control tumors, this could explain the reduced time to recurrence, 
rather than effects of Cerk following HER2/neu down-regulation. To address the potential 
confounding effects of Cerk expression during primary tumor formation, we modified the 
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orthotopic recurrence assay to eliminate primary tumor formation, thereby isolating the effects 
of Cerk on tumor cell survival and recurrence. 
Recipient mice pretreated with doxycycline were injected with control or Cerk 
overexpressing cells and then withdrawn from doxycycline after 48 hr, before primary tumors 
had formed (Figure 2.4D). Consistent with our prior results, Cerk overexpression accelerated the 
rate of mammary tumor recurrence and reduced the median time to recurrence from 304 days 
in controls to 185 days in the presence of Cerk expression (Figure 2.4E, HR = 3.64, p = 0.002). 
Again, mean growth rate was not found to be different between control and Cerk 
overexpressing cohorts (Figure 2.4F). These results indicate that Cerk can promote mammary 
tumor recurrence following HER2/neu down-regulation and that this effect is unlikely to be due 
to Cerk-induced alterations in primary tumor formation. 
 
Elevated CERK expression is associated with an increased risk of recurrence in women with 
breast cancer 
A prior report suggested that elevated CERK expression is associated with poor 
prognosis in ER-negative breast cancer patients (190). To confirm and extend this analysis, we 
interrogated publicly available human breast cancer expression datasets corresponding to 2,224 
patients with tumors of mixed ER status in order to evaluate the association of CERK expression 
with recurrence-free survival in a meta-analysis. Using a Cox proportional hazards (PH) model, 
we found that women with primary tumors expressing high levels of CERK exhibited an 
increased risk of tumor recurrence within five years of diagnosis (Figure 2.5, HR = 1.32 [1.17 – 
1.49]). 
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We next asked whether CERK expression is associated with aggressive subtypes of 
breast cancer. Association studies revealed that CERK is expressed at higher levels in ER-
negative compared to ER-positive, and PR-negative compared to PR-positive, tumors. CERK 
expression was also associated with HER2-positive status as assessed by immunohistochemistry 
(Figure 2.6A-C). Evaluation of CERK expression as a function of molecular subtype revealed that 
CERK expression is higher in the basal and ErbB2 subtypes compared to the luminal A and 
luminal B subtypes (Figure 2.6D). CERK expression was also associated with high tumor grade 
(Figure 2.6E), but not with tumor size or lymph node status (data not shown). 
Since ER-negative, PR-negative, HER2-positive, basal-like and high grade tumors are 
each associated with a poor prognosis, we wished to determine whether the association 
between CERK expression and relapse-free survival in breast cancer patients was independent 
of the association between CERK expression and these aggressive tumor subsets. To address 
this, we performed multivariate Cox proportional hazards regression in combination with meta-
analyses and adjusted for each of these variables individually. In each case, we found that the 
association between elevated CERK expression and decreased recurrence-free survival remained 
significant after adjusting for ER status, PR status, HER2 status, molecular subtype or tumor 
grade (Figure 2.7A–E). Influence analysis performed on each significant result obtained by meta-
analysis confirmed that these results were independent of any single dataset (Figure 2.8). 
In aggregate, our results indicate that CERK expression in human breast cancer is 
associated with an increased risk of recurrence within five years, and is independent of the 
association between CERK expression and aggressive subtypes of human breast cancer. 
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Discussion 
The importance of ceramide metabolism in cancer has become of increasing interest in 
recent years (53,107,197). However, relatively little functional data have emerged in describing 
ceramide, its metabolites and the metabolic enzymes responsible for their generation in 
tumorigenesis and tumor progression. 
In a number of tumor cell lines, Cerk has been reported to exert cytoprotective effects 
in a variety of in vitro contexts, including serum starvation, TNFα signaling and UV irradiation. To 
date, however, no evidence has existed for a functional role for Cerk in tumor cell survival in 
vivo, tumor progression or tumor recurrence. Using genetically engineered mouse models, 
human breast cancer cell lines and expression data from breast cancer patients, we have now 
identified a functional role for Cerk as a regulator of tumor cell survival and breast cancer 
recurrence following HER2/neu down-regulation.  
We found that Cerk is spontaneously up-regulated during the process of tumor 
recurrence in mammary tumors driven by four different oncogenic pathways. Notably, Cerk was 
up-regulated as early as 96 hr following oncogene down-regulation in mice bearing HER2/neu-
driven mammary tumors and, consistent with this, human HER2/neu-amplified breast cancer 
cell lines also rapidly up-regulated Cerk following HER2/neu pathway inhibition. Indicative of a 
role for Cerk in the context of HER2/neu inhibition, enforced Cerk expression inhibited 
apoptosis. 
In accord with the anti-apoptotic effects of Cerk in tumor cells following HER2/neu 
down-regulation, Cerk expression in orthotopic primary mammary tumor cells promoted tumor 
recurrence, indicating a functional role for Cerk in this stage of tumor progression. In aggregate, 
our findings indicate that Cerk is required for tumor cell survival following HER2/neu down-
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regulation. Ostensibly, this may result in a larger pool of surviving residual tumor cells that can 
potentially give rise to recurrent tumors. These findings therefore suggest a therapeutic 
opportunity whereby inhibition of Cerk in concert with treatment with targeted therapies may 
enhance tumor cell death, reduce the reservoir of residual tumor cells, and thereby prevent 
tumor recurrence. 
In agreement with its functional role in mammary tumor recurrence elucidated in mice, 
CERK was associated with increased risk of recurrence in human breast cancer patients. CERK 
expression was associated with aggressive subtypes of breast cancer, including ER-negative, PR-
negative, HER2-positive, high grade, and ErbB2 and basal-like tumors. However, the association 
between CERK and relapse-free survival was independent of its association with these 
aggressive subsets of tumors. As such, while CERK was previously reported to be associated with 
decreased recurrence-free survival in ER-negative breast cancer patients (190), our findings 
extend this analysis by demonstrating that CERK is associated with poor outcome in all breast 
cancer patients and does so independently of its association with individual aggressive 
prognostic factors. 
In aggregate, our findings may identify Cerk as a pathway for cell survival in breast 
cancer cells, as well as define a subset of human breast cancers with a high likelihood of relapse. 
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Materials and Methods 
Animals and Orthotopic Recurrence Assays 
All animal experiments were performed in accordance with guidelines of the 
Institutional Animal Care and Use Committee at the University of Pennsylvania. MTB/TAN, 
MTB/TOM, MTB/TWNT;p53+/- and MTB/TAKT mice were bred and tumors were generated as 
previously described (45–48). Orthotopic recurrence assays and competition assays were 
performed as described (49,198). Athymic (nu/nu) mice were obtained from Taconic 
(Germantown, NY).  
 
Tissue Culture and Reagents 
Primary MTB/TAN tumor cells were cultured as described in the presence of doxycycline 
(49,198). Primary tumor cells were transduced with retrovirally-packaged mCerk cDNA.  
BT474, SKBR3 and BT20 cells were purchased from ATCC. All cells were cultured at 37°C 
with 5% CO2. BT474 cells were cultured in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS), 1% Penicillin/Streptomycin and 1% L-glutamine. SKBR3 cells were cultured 
in McCoy’s 5A modified medium supplemented with 10% FBS, 1% Penicillin/Streptomycin and 
1% L-glutamine. BT20 cells were cultured in EMEM medium supplemented with 10% FBS, 1% 
Penicillin/Streptomycin and 1% L-glutamine. 
 
Plasmids and RNAi 
The cDNA for mCerk (MMM1013-202798251, Open Biosystems) was subcloned into the 
pk1 vector as described (199). Mutation of the glycine residue at position 198 of human CERK to 
aspartate was previously shown to generate a catalytically inactive Cerk mutant (156). After 
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confirming this residue to be conserved in mouse, we generated the G198D mutant mCerk using 
site-directed mutagenesis. Using the Quickchange Lightning Site-Directed Mutagenesis kit 
(Agilent Technologies), we generated the primers G198D-F (forward, 5'-
CGTAGGTGGGGACGACATGTTCAGCGAGG-3') and G198D-R (reverse, 5'-
CCTCGCTGAACATGTCGTCCCCACCTACG-3'), and performed the mutagenesis reaction according 
to manufacturer’s instructions. 
cDNA plasmids were virally packaged using Plat-E cells (Morita et al., 2000), which were 
transfected with retroviral constructs using Lipofectamine® 2000 (Life Technologies). 
Supernatant containing viral particles was collected 48 hr post-transfection, filtered and used to 
infect primary tumor cell lines. Transduction was performed in the presence of 4 µg/ml 
polybrene (Millipore). 
 
Antibodies 
The following antibodies were used as indicated throughout the text: cleaved caspase-3 
(Cell Signaling), cleaved PARP (Cell Signaling), Ki67 (Dako), β-Tubulin (Biogenex). 
 
Immunoblotting 
Protein lysates were generated by homogenizing cells in RIPA buffer (50 mM Tris pH 8.0, 
150 mM NaCl, 1% NP40, 0.5% NaDOC, 0.1% SDS) supplemented with HALTTM Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific). 
Secondary antibodies conjugated to IRDye 800CW (LI-COR Biosciences) were used. 
Odyssey V3.0 system (LI-COR Biosciences) was used to visualize and quantify proteins of 
interest. Quantification was performed using ImageStudio software (LI-COR Biosciences). 
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Immunofluorescence and Microscopy 
For immunofluorescence studies of tumor tissue from the competition assay, tumors 
were snap-frozen in OCT (TissueTek) and cut into 8 µm frozen sections. Sections were fixed in 
4% PFA for 10 min then stained with Hoechst 33258 (Sigma). For cleaved caspase-3 staining, 
tumors were fixed in 4% PFA in PBS overnight then embedded in paraffin. Sections were 
prepared using a standard xylene-based de-waxing procedure, then subjected to antigen 
retrieval and stained with appropriate primary and secondary antibodies. 
For cell culture experiments, cells were seeded on 4-chamber slides, fixed in 4% PFA for 
10 min then permeabilized with 0.5% Triton in PBS for 20 min. Slides were then stained with 
corresponding primary and secondary antibodies. Fluorescence and immunofluorescence 
microscopy were performed on a DM 5000B Automated Upright Microscope (Leica). Images 
were captured with a DFC350 FX monochrome digital camera (Leica). 
 
RNA Isolation and Quantitative RT-PCR 
RNA was isolated from tumors using Trizol (Invitrogen) followed by RNeasy® RNA Mini 
Kit (Qiagen). RNA was isolated from cells using the RNeasy® RNA Mini Kit (Qiagen). Reverse 
transcription was performed using the High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) according to manufacturer’s instructions. qPCR was performed on the ViiaTM 7 Real-
Time PCR System (Life Technologies) using 6-carboxyfluorescein-labeled Taqman probes for 
mCerk, hCerk, mTBP and hTBP (Applied Biosystems). Relative expression levels were calculated 
using the comparative CT method. 
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Statistical Analyses 
Unpaired Student’s t-tests were utilized to analyze normally distributed data. Mann-
Whitney U tests were used when data were not normally distributed. Two-way ANOVAs were 
used to compare paired data. Log-rank tests were used to analyze survival curves. p-values < 
0.05 were considered statistically significant. Hazard ratios with 95% confidence intervals were 
calculated for all survival curves. 
 
Human Breast Cancer Microarray Data Analysis 
We obtained publicly available microarray data and the corresponding clinical 
annotations from 14 data sets encompassing 2,224 breast cancer patients (200–213). 
Normalized data were downloaded from NCBI GEO or original authors’ websites. Microarray 
data were converted to base-2 log scale where necessary. Affymetrix microarray data were re-
normalized using Robust Multi-array Average when .CEL files were available. 
Association between Cerk mRNA expression and 5-year relapse-free survival was 
estimated using meta-analysis of univariate Cox proportional hazards regression as previously 
described (198). Meta-analyses were performed in subsets of patients stratified by ER status, PR 
status, HER2 status, molecular subtype and tumor grade as described (198). Influence analyses 
were performed on all significant findings derived by meta-analysis to determine whether the 
significant result was independent of any single dataset. 
The association between Cerk mRNA expression and known prognostic factors of human 
breast cancer such as ER status, PR status, HER2 status, lymph node status, tumor size, tumor 
grade and molecular subtype was assessed by ANOVA in pooled microarray datasets as 
previously described (198).  
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For each prognostic factor significantly associated with Cerk mRNA expression, we re-
assessed the association between Cerk mRNA expression and relapse-free survival after 
adjusting for the prognostic factor in a multivariate Cox proportional hazards model. The 
adjusted hazard ratios and confidence intervals for Cerk mRNA expression were aggregated 
across multiple data sets and assigned an overall significance using meta-analysis as described 
above. 
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Figure 2.1: Cerk is spontaneously up-regulated in recurrent mammary tumors and following 
acute HER2/neu inhibition 
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(A) qRT-PCR analysis of Cerk mRNA expression in primary and recurrent HER2/neu, c-MYC, Wnt1, 
and Akt1-driven tumors. (B) qRT-PCR analysis of Cerk mRNA expression from MTB/TAN tumors 
at primary, 48 hr deinduced, 96 hr deinduced, and recurrent time points. (C) qRT-PCR analysis of 
Cerk mRNA expression in primary MTB/TAN tumor cell line in vitro removed from doxycycline 1, 
2, 4 or 6 days. (D) qRT-PCR analysis of CERK mRNA expression in BT474 cells and (E) SKBR3 cells 
treated with 100 nM lapatinib or DMSO for 1, 2 or 3 days. qRT-PCR analysis of CERK mRNA 
expression in (F) BT20 cells and (G) primary MTB/TAN cells treated with 10 µM adriamycin or 
vehicle for 4, 8, 16 or 24 hr. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 2.2. Cerk protects cells from apoptosis upon HER2/neu down-regulation in vitro 
 
(A) Representative fluorescence images and (B) quantification of MTB/TAN primary tumor cell 
lines expressing empty vector, Cerk or G198D-Cerk withdrawn from doxycycline 72 hr then 
stained for cleaved caspase-3 (red; Hoechst = blue). (C) Quantification of MTB/TAN primary 
tumor cell lines expressing empty vector, Cerk or G198D-Cerk withdrawn from doxycycline 72 hr 
then stained for Ki67. (D) Western blot of MTB/TAN primary tumor cell lines expressing empty 
vector, Cerk or G198D-Cerk withdrawn from doxycycline 48 hr, blotted for cleaved PARP, 
quantified in (E), and cleaved caspase-3, quantified in (F). *p<0.05, **p<0.01, ***p<0.001.  
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Figure 2.3. Cerk promotes tumor cell survival in vivo following HER2/neu down-regulation 
 
(A) Quantification of cleaved caspase-3 staining in primary orthotopic empty vector, Cerk and 
G198D-Cerk tumors at 48 and 96 hr post-deinduction. (B) Representative fluorescence images of 
primary tumors, 48 hr and 96 hr deinduced tumors stained for cleaved caspase-3 (red; Hoechst 
= blue). *p<0.05, **p<0.01, ***p<0.001.  
53 
 
Figure 2.4. Cerk promotes tumor recurrence in the MTB/TAN model. 
 
(A) Schematic of recurrence assay and timing of doxycycline treatment. (B) Recurrence-free 
survival of nude mice harboring primary orthotopic tumors from MTB/TAN primary cell lines 
expressing empty vector or overexpression Cerk induced to regress by doxycycline withdrawal. 
(C) Mean growth rate of control and Cerk overexpressing recurrent tumors. (D) Schematic of 
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modified recurrence assay with no primary tumor formation. (E) Recurrence-free survival of 
nude mice harboring MTB/TAN primary cell lines expressing empty vector or overexpressing 
Cerk withdrawn from doxycycline 48 hr post-injection. (F) Mean growth rate of control and Cerk 
overexpressing recurrent tumors.   
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Figure 2.5. High CERK expression predicts decreased relapse-free survival in women with 
breast cancer 
 
Forest plot representation of 5-year survival estimates and hazard ratios for relapse-free survival 
of individual datasets of human breast cancer patients.   
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Figure 2.6. CERK expression in human breast cancer subsets 
 
Association between CERK mRNA expression and (A) ER status, (B) PR status, (C) HER2 status, (D) 
molecular subtype and (E) tumor grade in pooled datasets of human breast cancer patients. 
Each variable was analyzed by ANOVA.   
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Figure 2.7. Multivariate analysis of the association of CERK expression and relapse-free 
survival after adjusting for subsets 
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Forest plot representation of 5-year survival estimates and hazard ratios after adjusting for the 
impact of: (A) ER status, (B) PR status, (C) HER2 status, (D) molecular subtype and (E) tumor 
grade. Multivariate analysis was performed to assess the hazard ratio (HR) in individual datasets. 
Overall p-value and HR were calculated by meta-analysis.   
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Figure 2.8. Influence analysis 
 
Influence analyses were performed on all significant p-values derived by meta-analysis to 
determine whether the significant result was independent of any single dataset.   
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CHAPTER 3: Loss-of-Function Cerk Experiments 
Introduction 
In Chapter 2, we provided evidence that Cerk protects tumor cells from apoptosis upon 
oncogene down-regulation and promotes mammary tumor recurrence. Cerk overexpression 
inhibited apoptosis in MTB/TAN primary tumor cell lines in vitro and in orthotopic tumors in vivo 
following HER2/neu down-regulation as indicated by decreases in cleaved caspase-3. This was 
demonstrated to be dependent on Cerk’s kinase activity, as the kinase dead mutant G198D-Cerk 
did not protect cells or tumors from apoptosis. Furthermore, Cerk overexpression markedly 
accelerated tumor recurrence in an orthotopic model, illustrating its functional role in tumor 
progression. 
Having shown the relevance of Cerk in tumor cell survival and in mammary tumor 
progression by gain-of-function experiments, loss-of-function experiments are crucial to 
determine whether inhibition of Cerk would have therapeutic potential. Genetic experiments 
knocking down Cerk are specific relative to pharmacological agents and important in 
determining the effect of loss of Cerk. Also, two small molecule inhibitors of Cerk have been 
developed, NVP-231 (186) and K1 (187,188), described in detail in Chapter 1. However, they 
have not been thoroughly tested in vitro and have not been characterized at all in vivo, the 
reason for which appears to be low bioavailability for NVP-231. In vivo studies with K1 have not 
been published to date. Inhibitors with better pharmacokinetic profiles will likely need to be 
developed in order to have potential use in vivo and in the clinic. 
Mice lacking both alleles of Cerk are phenotypically normal, except for neutropenia 
induced by apoptosis in granulocytes, which is associated with increased ceramide levels (167). 
Tumor forming ability has not been assessed in these mice, however, endothelial cells derived 
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from Cerk-/- mice display a VEGF-independent defect in angiogenesis (214). Cerk-/- mice have yet 
to be tested in conjunction with oncogene-driven cancer models. This would provide very 
specific answers as to the role of Cerk in tumorigenesis and tumor progression. For example, 
crossing Cerk-/- mice with MMTV-rtTA;TetO-HER2/neu, MMTV-rtTA;TetO-MYC, MMTV-
rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 transgenic mice would provide evidence for 
the role of Cerk in tumorigenesis driven by specific oncogenes.  Very few shRNA knockdown 
experiments have been performed with Cerk, although some insight has been obtained from 
Cerk-/- cells and treatment with NVP-231 or K1 in vitro (186,187,214). 
Whether inhibition of Cerk with small molecules will be a successful approach in the 
context of cancer remains to be elucidated. Some studies suggest that inhibition of Cerk activity 
may not be sufficient to cause cell cycle arrest or death, but may sensitize cells to cytotoxic 
agents (186), providing insight into potential for combination therapy. 
In this chapter, we attempt to elucidate the effect of loss-of-function of Cerk and its 
effect on tumor cell survival and mammary tumor recurrence. First, we generated Cerk 
knockdown MTB/TAN primary tumor cell lines and tested them for sensitivity to apoptosis in the 
context of HER2/neu down-regulation. We then tested these cell lines in vivo in orthotopic 
recurrence assays and orthotopic cellular competition assays. Due to difficulty maintaining 
shRNA knockdown of Cerk in in vivo experiments, we describe an attempt to characterize and 
troubleshoot a conditional shRNA expression system in vitro and in vivo.  
We obtained the Cerk inhibitor NVP-231 from Novartis to conduct pharmacological 
studies on human breast cancer cell lines to determine whether inhibition of Cerk would 
sensitize cells to apoptosis. These studies demonstrated that only at very high doses does NVP-
231 synergize with lapatinib to provide high levels of caspase activity indicating apoptosis. This is 
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unlikely to be attributable solely to Cerk inhibition as the doses of inhibitor used were in the 
millimolar range. To test the potential synergistic effect of Cerk inhibition with EGFR and 
HER2/neu inhibition by lapatinib genetically, we knocked down CERK in BT474 cells treated with 
lapatinib. 
Lastly, having demonstrated a role for Cerk in cell survival acutely following HER2/neu 
down-regulation, we wished to address the question of whether Cerk has a role in actively 
proliferating primary and/or recurrent MTB/TAN tumor cell lines in an orthotopic setting in vivo. 
We knocked down Cerk in one primary and two recurrent MTB/TAN tumor cell lines and 
evaluated tumor growth in vivo. The results from these experiments leave many questions that 
must be addressed to fully characterize Cerk’s potential as a drug target in cancer.  
In aggregate, our findings about the difficulty in maintaining Cerk knockdown in 
orthotopic recurrence assays in vivo may indicate a strong dependence of tumor cell lines on 
Cerk signaling, which in turn may indicate that Cerk has potential as a drug target in cancer cells. 
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Results 
Cerk knockdown sensitizes tumor cells to apoptosis in vitro following HER2/neu down-
regulation 
A previous report demonstrated that siRNA targeting Cerk sensitized A549 lung 
adenocarcinoma cells to apoptosis following serum deprivation (178). To determine whether 
loss of function of Cerk would sensitize cells to apoptosis following HER2/neu down-regulation, 
we withdrew doxycycline from the culture media of primary MTB/TAN tumor cells expressing 
either of two Cerk shRNAs, a scrambled control shRNA or an empty vector control. Cells were 
then stained for cleaved caspase-3 and Ki67. Cerk knockdown cells exhibited markedly increased 
staining for cleaved caspase-3 compared to control cells following doxycycline withdrawal 
(Figure 3.1A, B). Proliferation rates fell dramatically upon HER2/neu down-regulation, but were 
not significantly different between control and Cerk knockdown cells (Figure 3.1C). These 
findings suggest that Cerk is required for the suppression of apoptosis following HER2/neu 
down-regulation. Similarly, by Western blot, Cerk knockdown cell lines exhibited significantly 
higher levels of cleaved PARP and cleaved caspase-3 than controls following doxycycline 
withdrawal (Figure 3.1D-I). 
 
Cerk is required for tumor cell survival following HER2/neu down-regulation in vivo 
To expand our in vitro findings that Cerk protects tumor cells from apoptosis upon 
HER2/neu pathway inhibition, we sought to test this in vivo. To determine whether Cerk is 
required for the survival of tumor cells following acute HER2/neu down-regulation, we 
performed an orthotopic fluorescent cell competition assay using an isogenic pair of 
doxycycline-dependent MTB/TAN tumor cell lines that differed only in Cerk expression. 
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MTB/TAN primary tumor cells expressing one of two shRNAs targeting Cerk were labeled with 
an H2B-eGFP reporter, whereas MTB/TAN cells transduced with a control vector were labeled 
with an H2B-mCherry reporter (Figure 3.2A). These two fluorescent populations of cells were 
injected into the mammary glands of nu/nu mice at a 1:1 ratio and allowed to form orthotopic 
primary tumors in the presence of doxycycline and HER2/neu expression. Doxycycline was then 
withdrawn to initiate tumor regression and the ratio of eGFP-labeled Cerk knockdown cells to 
mCherry-labeled control cells was determined in primary tumors, residual tumor cells 96 hr 
following HER2/neu down-regulation, and residual tumor cells 28 days following HER2/neu 
down-regulation by fluorescence microscopy performed on histological sections (Figure 3.1B). 
Cerk shRNA-expressing cells were neither selected for nor against during the outgrowth 
of primary orthotopic tumors (Figure 3.1C, D, F), indicating that Cerk knockdown does not confer 
a selective advantage or disadvantage during primary tumorigenesis in the presence of 
HER2/neu expression. In contrast, eGFP-labeled Cerk knockdown cells were strongly selected 
against within 96 hr following doxycycline withdrawal and HER2/neu down-regulation, as these 
cells comprised only 20-25% of the fluorescent tumor cells at this time point (Figure 3.1C, D, F). 
By 28 days following doxycycline withdrawal, Cerk knockdown cells comprised only 14-20% of 
fluorescent cells, indicating modest further negative selection against Cerk knockdown cells 
(Figure 3.1C, D, F). Tumors containing control mCherry-labeled cells and control eGFP-labeled 
cells maintained an approximately 1:1 ratio throughout tumor progression through all these 
time points (Figure 3.1E). These findings indicate that cells in which Cerk has been knocked 
down are rapidly and persistently selected against following HER2/neu down-regulation, but not 
in actively growing primary tumor cells expressing HER2/neu. 
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Cerk knockdown recurrence assays 
Having observed strong selection against cells containing Cerk shRNAs in the context of 
an orthotopic cellular competition assay, we sought to determine whether Cerk knockdown 
would delay tumor recurrence. To determine whether Cerk is required for tumor recurrence, we 
injected primary MTB/TAN tumor cells expressing either of two Cerk shRNAs, a scrambled 
control shRNA or an empty vector control into the mammary fat pads of nu/nu mice maintained 
on doxycycline. Analogous to experiments detailed in Figure 2.4A, following primary tumor 
formation, mice were withdrawn from doxycycline to induce oncogene down-regulation and 
tumor regression, then monitored for tumor recurrence.  
Unexpectedly, although enforced expression of Cerk markedly accelerated tumor 
recurrence (Figure 2.4B, E), Cerk knockdown cohorts did not display delayed tumor recurrence 
as median time to recurrence did not differ significantly between any of the cohorts (Figure 
3.3A). To investigate why Cerk knockdown did not alter the kinetics of recurrence, we harvested 
primary tumors from these animals, extracted RNA and performed qRT-PCR to quantify Cerk 
expression. Despite having seen greater than 65% knockdown in cell lines in vitro prior to 
injection (Figure 3.2A), we did not observe any measurable knockdown in primary tumors 
generated in mice injected with Cerk knockdown cells (Figure 3.3B). This may explain why no 
effect was observed on latency to tumor recurrence. This suggests that Cerk knockdown may 
not be compatible with tumor growth and must be circumvented for tumors to form. 
In an attempt to isolate the effects of Cerk knockdown on tumor recurrence and avoid 
the loss of knockdown occurring during the process of primary tumor formation, we used a 
modified recurrence assay described in Figure 2.4D. Recipient mice pretreated with doxycycline 
were injected with cells expressing either of two Cerk shRNAs, a scrambled control shRNA or an 
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empty vector control and then withdrawn from doxycycline after 48 hr, before primary tumors 
had formed.  
Despite the modification of the recurrence assay to eliminate the potentially 
confounding effects of primary tumor formation, we observed no effect on recurrence-free 
survival between Cerk knockdown and control cohorts (Figure 3.3C). qRT-PCR analysis of 
recurrent tumors from these animals showed no detectable Cerk knockdown (Figure 3.3D), 
consistent with the loss of knockdown seen in the primary tumors of the original recurrence 
assay (Figure 3.3B). This indicated that Cerk knockdown is not be sustained throughout tumor 
recurrence, potentially due to selection against cells with high Cerk knockdown, to Cerk 
upregulation, or to shRNA silencing. Therefore, to address whether Cerk was required for tumor 
recurrence, a different approach became necessary. 
 
FLIPi conditional shRNA expression system 
We turned to the FLIPi conditional expression system developed by the laboratory of 
Richard Hynes (215). This system allows for Cre-regulated expression of shRNAs, with a GFP 
reporter prior to recombination and an mCherry reporter following recombination. We hoped 
this system would permit controlled expression of shRNAs targeting Cerk at specific timepoints 
throughout tumor progression, circumventing the loss of knockdown seen with a constitutive 
shRNA expression system.  
We first sought to confirm the ability of this vector to undergo Cre-mediated 
recombination in vitro. As we received the FLIPi vector with a p53 shRNA (FLIPi-shp53), we 
utilized this form of the vector for testing and transduced it into our primary MTB/TAN cell line. 
Treatment with adenoviral (adeno)-Cre led to efficient recombination, as monitored by 
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transition from GFP expression to mCherry expression and p53 knockdown detectable by qRT-
PCR (data not shown; performed by Lauren Pferdehirt).  
To address the requirement for Cerk in tumor recurrence in vivo, this system required 
adaptation, as no route of administration was known to efficiently deliver adeno-Cre to all cells 
in a solid mammary tumor. Instead, a tamoxifen-inducible Cre-expressing MTB/TAN mouse cell 
line would allow recipient mice to be treated with tumor-permeable tamoxifen by oral gavage in 
order to induce recombination. To that end, we crossed bitransgenic MTB/TAN mice with Ubc-
CreERT2 mice to generate triple-transgenic MTB/TAN;Ubc-CreERT2 offspring. At six weeks of age, 
female MTB/TAN;Ubc-CreERT2 mice were administered doxycycline through drinking water to 
induce tumor formation. Once tumors had formed, the animals were sacrificed, their tumors 
excised, minced, then digested with collagenase, hyaluronidase, and trypsin. Tumor cells were 
plated in culture to generate stable cell lines. Despite many attempts, only one stable cell line 
was generated that was capable of continued passaging in vitro.  
 
Testing of FLIPi in MTB/TAN;Ubc-CreERT2 cell line in vitro 
MTB/TAN;Ubc-CreERT2 cells were transduced with the FLIPi-shp53 vector for testing of 
recombination following tamoxifen treatment. Cells were selected with puromycin for one week 
prior to testing. Puromycin was removed from the culture media prior to recombination testing, 
as the puromycin resistance cassette is excised upon recombination (215). As tamoxifen is a pro-
drug that becomes hydroxylated by CYP450 enzymes in vivo, we utilized 4-OH-tamoxifen for in 
vitro testing (216). Cells were treated with 100, 150, 200, 250 or 300 nM 4-OH-tamoxifen for 24 
or 48 hr. The majority of untreated cells were GFP-positive and exhibited very rare spontaneous 
recombination, monitored by mCherry expression, even when cultured in the absence of 
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puromycin for several passages (Figure 3.4A). Following 24 hr treatment with any dose of 4-OH-
tamoxifen, most cells still expressed GFP but also expressed mCherry (Figure 3.4A). By 48 hr 
treatment, most cells expressed detectable mCherry and GFP expression was significantly 
decreased (Figure 3.4B). GFP expression was no longer detectable at 96 hr at any dose of 
treatment (data not shown). These results confirmed that this system is capable of tightly 
controlled recombination induced by 4-OH-tamoxifen in vitro. 
 
Characterizing MTB/TAN;Ubc-CreERT2 cell line in vivo 
To test whether the MTB/TAN;Ubc-CreERT2 cell line could be used in vivo for orthotopic 
recurrence assays, we sought to characterize its tumor forming ability, tumor morphology, 
dependence on doxycycline, and ability to recur following oncogene-downregulation. We 
injected the parental MTB/TAN;Ubc-CreERT2 cell line into the mammary fat pads of nu/nu mice 
maintained on doxycycline. Following primary tumor formation, one cohort was sacrificed for 
harvest of primary tumors. The remaining animals were withdrawn from doxycycline to induce 
oncogene down-regulation and tumor regression. All tumors regressed to a non-palpable state. 
Mice were then monitored for tumor recurrence.  
Primary tumors exhibited a highly epithelial morphology (Figure 3.4C), with structures 
mirroring the intact tumor from which this cell line originated. All animals withdrawn from 
doxycycline displayed stochastic mammary recurrence with a median of 246 days. This confirms 
that this MTB/TAN;Ubc-CreERT2 cell line is capable of primary tumor formation, is dependent on 
doxycycline, forms epithelial tumors, and exhibits a highly penetrant recurrence phenotype.  
  
69 
 
Testing of FLIPi recombination in MTB/TAN;Ubc-CreERT2 cell line in vivo 
Having established the MTB/TAN;Ubc-CreERT2 cell line’s suitability for orthotopic 
recurrence assays, we wished to determine whether the FLIPi vector could be recombined 
efficiently in this cell line in vivo. We injected MTB/TAN;Ubc-CreERT2 cells transduced with FLIPi-
shp53 into the mammary fat pads of nu/nu mice maintained on doxycycline. Primary tumors of 
5 x 5 mm were allowed to form, animals were then treated with vehicle for 1, 3, or 5 days, 
treated with tamoxifen 1, 3, or 5 days by oral gavage, or sacrificed. All treated animals were 
sacrificed 72 hr after the final treatment to provide time for degradation of GFP and expression 
of detectable levels of mCherry. 
Tumors from untreated and vehicle treated animals were 100% GFP-positive at all 
timepoints, with no detectable mCherry expression, indicating an absence of spontaneous 
recombination (Figure 3.5A). Tumors from tamoxifen-treated animals underwent efficient 
recombination at all timepoints, exhibiting strong mCherry expression (Figure 3.5B, C, D). 
Residual GFP expression was detectable in tumors treated for one day (Figure 3.5B), but not in 
tumors treated for 3 or 5 d. Therefore, the 3 d treatment course was chosen for further 
experiments.  
 
Recurrence assays with MTB/TAN;Ubc-CreERT2 cell line 
Having identified an optimal treatment course for efficient recombination in vivo, we 
sought to answer the question of whether Cerk is required for tumor recurrence. We set out to 
test whether Cerk shRNA expression using this conditional system would have an effect on 
latency of recurrence. We cloned two Cerk-targeting shRNAs as well as our scrambled control, 
previously tested in the MLP vector, into the FLIPi vector. We also generated an empty vector by 
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blunt-end ligation. These constructs were transduced into the MTB/TAN;Ubc-CreERT2 cell line, 
then injected into the mammary fat pads of nu/nu mice maintained on doxycycline. Primary 
tumors were allowed to form, then animals were treated by oral gavage for three consecutive 
days with tamoxifen or vehicle. Mice were either sacrificed or removed from doxycycline on the 
fourth day. All tumors regressed to a non-palpable state, regardless of Cerk knockdown status or 
treatment regimen. Another cohort was sacrificed 96 hr post-deinduction. The remaining 
animals were monitored for tumor recurrence. 
Despite tightly-regulated and efficient recombination assessed by GFP or mCherry 
fluorescence at sacrifice, the presence of Cerk shRNAs did not affect recurrence-free survival in 
these animals. Median time to recurrence was not significantly altered in any of the cohorts, 
whether treated with tamoxifen (Figure 3.6A) or with vehicle (Figure 3.6B). qRT-PCR analysis 
revealed that Cerk expression in tumors arising from Cerk shRNA, scrambled or vector control 
cells was not significantly different at any timepoint, and was not altered by treatment with 
tamoxifen over vehicle (Figure 3.6C). 
 
Troubleshooting FLIPi shRNA expression in vitro  
Having observed no effect of FLIPi-shCerk recombination on tumor recurrence in the 
orthotopic recurrence assay and no detectable Cerk knockdown in vivo at any timepoint, we 
sought to determine whether Cerk was being effectively knocked down in this system in vitro. 
Upon recombination, the FLIPi vector produces a single transcript with the mCherry reporter 
followed by the shRNA. The transcript is then spliced at sites flanking the shRNA. Therefore, as a 
surrogate for Cerk shRNA expression, we interrogated GFP and mCherry expression levels in 
MTB/TAN;Ubc-CreERT2 cell lines with Cerk shRNAs compared to an empty vector control before 
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and after 4-OH-tamoxifen treatment. In a different context, we had observed a bimodal 
distribution of cells expressing low and high levels of fluorophores (data not shown, performed 
by James Alvarez), which was hypothesized to correlate with levels of shRNA expression, which 
may in turn lead to reduced knockdown detected globally. If true, this could provide an avenue 
to allow us to sort for high levels of fluorophore expression to obtain higher levels of shRNA 
expression and therefore better shRNA-mediated knockdown of Cerk. However, we did not 
observe a bimodal distribution of fluorophore expression either before or after treatment with 
4-OH-tamoxifen in vitro (Figure 3.7A), indicating that sorting out low-expressing cells is likely not 
a solution to obtain better shRNA-mediated knockdown of Cerk.  
As another method to potentially obtain better knockdown of Cerk with this system, we 
transduced cells twice with the same vector. MTB/TAN;Ubc-CreERT2 cells were transduced with 
each construct, selected with puromycin 72 hr post-transduction, grown for one week in the 
presence of puromycin, then transduced again with the same construct. Total RNA was 
extracted and qRT-PCR for Cerk expression was performed on cell lines following a single or 
double infection. Cerk expression was compared to that of MTB/TAN cell lines expressing one of 
two Cerk shRNAs, a scrambled hairpin or an empty vector control (MLPHG). Considerably less 
knockdown was obtained with the same shRNAs targeting Cerk in FLIPi in MTB/TAN;Ubc-CreERT2 
cell lines compared with MLPHG in MTB/TAN cells (Figure 3.7B). This does not explicitly address 
whether this is the result of the cell line or the expression system. Double infection with FLIPi 
vectors did not improve Cerk knockdown (Figure 3.7B). 
To directly interrogate levels of shRNA expression, we designed miRNA primer-probe 
sets against both Cerk-directed shRNAs to quantify expression of the shRNAs themselves. The 
total RNA extracted from singly and doubly infected MTB/TAN;Ubc-CreERT2 cell lines was utilized 
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for miRNA targeted RT and qPCR. Markedly lower levels of shRNA were expressed in FLIPi in 
MTB/TAN;Ubc-CreERT2 cell lines than in MLPHG in MTB/TAN cell lines (Figure 3.7C, D). Double 
infection appeared to moderately increase expression of Cerk shRNAs (Figure 3.7C, D), although 
this did not lead to improved knockdown (Figure 3.7B). These results indicate that insufficient 
shRNA expression may be the cause for undetectable levels of Cerk knockdown leading to 
undetectable effects on tumor recurrence in the orthotopic setting. This system will have to be 
optimized or altered to efficiently knock down Cerk and interrogate its role in tumor recurrence. 
 
High dose NVP-231 treatment may synergize with lapatinib in HER2/neu–amplified human 
breast cancer cells 
To employ pharmacological methods to inhibit Cerk, we obtained the Cerk inhibitor 
NVP-231 (Novartis) in order to assess whether pharmacological inhibition of Cerk would 
sensitize human breast cancer cell lines to apoptosis. We treated BT474 and SKBR3 cells with 
100 nM lapatinib or vehicle for 16, 24, or 48 hr along with increasing doses of NVP-231 from 100 
nM to 3 µM and assessed apoptosis with the Caspase Glo® 3/7 Assay System (Promega). At 
these points, 100 nM lapatinib did not lead to increases in luminescence, indicating that it did 
not induce caspase-3 and caspase-7 cleavage (Figure 3.8A-F). NVP-231 alone did not lead to 
significant increases in luminescence at any dose below 1 µM, and exhibited potentially 
synergistic effects with lapatinib at 3 µM, particularly in BT474 cells at 16 hr and in SKBR3 cells 
at 48 hr (Figure 3.8A, F). 
These studies seem to indicate that only at high doses of NVP-231 does it synergize with 
lapatinib to induce apoptosis, making it unlikely to be attributable solely to Cerk inhibition. 
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Further examination of pharmacological inhibition of Cerk, possibly with other agents, will be 
necessary to determine whether it is responsible for this effect. 
 
Cerk may not be required for actively proliferating primary and recurrent tumors 
We wanted to address the question of whether Cerk has a role in actively proliferating 
primary and/or recurrent MTB/TAN tumor cell lines in an orthotopic setting in vivo. We injected 
one primary and two recurrent MTB/TAN tumor cells expressing either of two Cerk shRNAs, a 
scrambled control shRNA or an empty vector control (Figure 3.9A) into the mammary fat pads of 
nu/nu mice maintained on doxycycline.  
Cerk knockdown in primary and recurrent cell lines did not alter growth kinetics as 
measured by tumor volume over time (Figure 3.9B, D, F) or as mean growth rate (Figure 3.9C, E, 
G). This may indicate that Cerk is not required for actively proliferating primary or recurrent 
tumors. However, this cannot distinguish between the possibility that Cerk knockdown may 
have been selected against or otherwise lost in early stages of tumor growth, precluding the 
appearance of a difference in tumor growth rate. This possibility cannot be eliminated as the 
tumors were not tested for Cerk expression. Future studies will have to address this caveat.  
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Discussion 
The inhibition of ceramide metabolic pathways is under investigation in many cancers 
and holds promise in clinical trials in combination with chemotherapy. Agents targeting 
glucosylceramide synthase (GCS) and sphingosine kinase (SphK) have been tested in clinical 
trials and hold promise as combination therapies in many cancers. Although Cerk has been 
shown to regulate cell survival in the context of many stresses including chemotherapy, 
radiotherapy and targeted therapy, the development and characterization of Cerk inhibitors is 
lagging behind that of other enzymes involved in ceramide metabolism. Only two small 
molecule inhibitors of Cerk have been identified to date. NVP-231 cannot be used in vivo due to 
poor pharmacokinetics (186), while K1 has never been tested in animals. Much work remains to 
be done to determine whether Cerk could be a successful drug target in human cancer patients. 
We found that Cerk knockdown sensitizes tumor cells to apoptosis upon doxycycline 
withdrawal and HER2/neu down-regulation in vitro. Furthermore, tumor cells in which Cerk had 
been knocked down were strongly selected against within 96 hr following HER2/neu down-
regulation, with further selection continuing into the dormant phase of tumor regression at 28 
days post-deinduction. Of note, we did not observe a selective effect against Cerk knockdown 
cells in the primary tumor of the orthotopic competition assay, indicating that Cerk expression in 
actively proliferating HER2/neu-driven tumor cells may not be rate limiting. This may also 
indicate that a non-cell autonomous mechanism may be at play.  
Based on published findings, we hypothesize that the paracrine secretion of PGE2 may 
be responsible for maintaining Cerk knockdown cells in primary tumors in the competition assay 
setting. Synthesis of C1P by Cerk is required for activation of cPLA2, which in turn releases 
arachidonic acid from membrane phospholipids for the synthesis of eicosanoids including 
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prostaglandins such as PGE2. PGE2 and other prostaglandins are then secreted and in an 
autocrine and paracrine manner bind to and activate PGE2 G-protein coupled receptors, leading 
to mitogenic signaling (Figure 1.2). This may allow Cerk knockdown cells to persist in primary 
tumors in a setting where Cerk knockdown is usually lost (Figure 3.3B). This suggests that cell-
autonomous mechanisms become important upon HER2/neu down-regulation, as Cerk 
knockdown cells were selected against very strongly within 96 hr despite the presence of control 
cells. 
The most abundant prostanoid in mammary tumors is PGE2, and high levels are 
associated with poor prognosis (217). PGE2 is known to promote inflammation and be pro-
tumorigenic (218). The role of chronic inflammation in tumorigenesis is well-established, and 
treatment with non-steroidal anti-inflammatory agents (NSAIDs) has been demonstrated to hold 
promise as a chemopreventive approach to some human cancers, including the four most 
prevalent cancers: breast, colon, lung and prostate (219–221). Cell-autonomous effects of 
prostanoids, especially PGE2, have been implicated in the activation of pro-tumorigenic signaling 
pathways, as exemplified by the stimulation of the Ras/Raf/MAP kinase and GSK3β – β catenin 
pathways downstream of the EP (PGE2) receptors (222). Also, effects of prostanoids on the 
mammary microenvironment, including stimulation of aromatase production in stromal fat cells, 
have been shown to stimulate tumor cell proliferation (223). Lastly, secreted prostanoids may 
have chemotactic functions for infiltrating neutrophils and macrophages that may have immune 
suppressive functions in situ (224,225). As such, the potential involvement of Cerk and C1P in 
eicosanoid-associated tumorigenesis would have important implications for the possible use of 
anti-inflammatory drugs in chemoprevention. 
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This also suggests that rate-limiting pathways regulating tumor cell growth and survival 
may differ depending upon the stage of tumor progression. As such, pharmacological agents 
that may be effective in treating primary breast cancers may have little effect in women with 
minimal residual disease or recurrent breast cancer. As such, the identification of 
pharmacological targets unique to these stages of tumor progression will be essential for 
improving long-term survival in this disease. Consequently, the inhibition of pathways that allow 
cells to survive therapy and eventually recur may be key to preventing the persistence of 
disseminated tumor cells and subsequence relapse. 
Although we were not able to demonstrate a requirement for Cerk in tumor recurrence 
in orthotopic tumor recurrence assays, future experiments delineated in Chapter 4 are expected 
to specifically address this question. This will help conclusively identify whether inhibition of 
Cerk is likely to be a successful target for therapy in the context of cancer, specifically those 
cancers refractory to chemotherapy or targeted therapy, in which Cerk inhibitors could be used 
in combination therapy regimens.  
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Materials and Methods  
Animals and Orthotopic Recurrence Assays 
All animal experiments were performed in accordance with guidelines of the 
Institutional Animal Care and Use Committee at the University of Pennsylvania. Orthotopic 
recurrence assays and competition assays were performed as described (49,198). Athymic 
(nu/nu) mice were obtained from Taconic (Germantown, NY). Mice treated with tamoxifen 
received 225 mg/kg tamoxifen by oral gavage for 1, 3 or 5 consecutive days. 
 
Tissue Culture and Reagents 
Primary MTB/TAN tumor cells were cultured as described in the presence of doxycycline 
(49,198). Primary tumor cells were transduced with retrovirally-packaged shRNAs targeting 
mCerk.  
 
Caspase-Glo and CellTiter-Glo Assays 
Viable cell number was measured using the CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega) and used to normalize caspase activity values measured with Caspase-Glo® 3/7 
Assay System (Promega). Briefly, cells grown in 96-well white-bottom plates were treated with a 
1:1 mixture of Caspase-Glo or CellTiter-Glo reagent and PBS (50μl per well), and gently shaken 
protected from light for 30 min at RT. Luminescence was measured using a GloMax 96-
Microplate Luminometer (Promega) with an integration time of 0.5 s. Experiments were 
performed in triplicate. 
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Plasmids and RNAi 
shRNAs targeting mCerk were designed using RNAi Central 
(http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA) and purchased from Open Biosystems. 
The following sequences were used: shCerk1 TGCTGTTGACAGTGAGCGCGCACTTGCTGGTATTCAT 
CAATAGTGAAGCCACAGATGTATTGATGAATACCAGCAAGTGCTTGCCTACTGCCTCGGA; shCerk2 
TGCTGTTGACAGTGAGCGAAGATTGTGTGTGTTACTCAACTAGTGAAGCCACAGATGTAGTTGAGTAACA
CACACAATCTG TGCCTACTGCCTCGGA. Oligonucleotides were cloned into the LMP vector (Open 
Biosystems), modified to express H2B-eGFP (referred to as MLPHG in the text) or H2B-mCherry 
as described (199).  
shRNA plasmids were virally packaged using Plat-E cells (Morita et al., 2000), which were 
transfected with retroviral constructs using Lipofectamine® 2000 (Life Technologies). 
Supernatant containing viral particles was collected 48 hr post-transfection, filtered and used to 
infect primary tumor cell lines. Transduction was performed in the presence of 4 µg/ml 
polybrene (Millipore). 
 
Antibodies 
The following antibodies were used as indicated throughout the text: cleaved caspase-3 
(Cell Signaling), cleaved PARP (Cell Signaling), Ki67 (Dako), β-Tubulin (Biogenex). 
 
Immunoblotting 
Protein lysates were generated by homogenizing cells in RIPA buffer (50 mM Tris pH 8.0, 
150 mM NaCl, 1% NP40, 0.5% NaDOC, 0.1% SDS) supplemented with HALTTM Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific). 
79 
 
Secondary antibodies conjugated to IRDye 800CW (LI-COR Biosciences) were used. 
Odyssey V3.0 system (LI-COR Biosciences) was used to visualize and quantify proteins of 
interest. Quantification was performed using ImageStudio software (LI-COR Biosciences). 
 
Immunofluorescence and Microscopy 
For immunofluorescence studies of tumor tissue from the competition assay, tumors 
were snap-frozen in OCT (TissueTek) and cut into 8 µm frozen sections. Sections were fixed in 
4% PFA for 10 min then stained with Hoechst 33258 (Sigma).  
For cell culture experiments, cells were seeded on 4-chamber slides, fixed in 4% PFA for 
10 min then permeabilized with 0.5% Triton in PBS for 20 min. Slides were then stained with 
corresponding primary and secondary antibodies. Fluorescence and immunofluorescence 
microscopy were performed on a DM 5000B Automated Upright Microscope (Leica). Images 
were captured with a DFC350 FX monochrome digital camera (Leica). 
 
RNA Isolation and Quantitative RT-PCR 
RNA was isolated from tumors using Trizol (Invitrogen) followed by RNeasy® RNA Mini 
Kit (Qiagen). RNA was isolated from cells using the RNeasy® RNA Mini Kit (Qiagen). Reverse 
transcription was performed using the High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems) according to manufacturer’s instructions. qPCR was performed on the ViiaTM 7 Real-
Time PCR System (Life Technologies) using 6-carboxyfluorescein-labeled Taqman probes for 
mCerk, hCerk, mTBP and hTBP (Applied Biosystems). Relative expression levels were calculated 
using the comparative CT method. 
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Total RNA was isolated from cells for detection of shRNAs using the miRNeasy® Mini Kit 
(Qiagen). Reverse transcription was performed with custom primers for shCerk1, shCerk2 and 
snoRNA202 as an internal control using the TaqMan® MicroRNA Reverse Transcription Kit (Life 
Technologies). qPCR was performed on the ViiaTM 7 Real-Time PCR System (Life Technologies) 
using 6-carboxyfluorescein-labeled Taqman probes for shCerk1, shCerk2 and SnoRNA202 
(Applied Biosystems). Relative expression levels were calculated using the comparative CT 
method. 
 
Flow Cytometry 
To measure the ratio of GFP- and mCherry-positive cells before and after 4-OH-
tamoxifen-induced recombination in vitro, cells were collected by trypsinization and fixed in 1% 
formaldehyde and 0.04% sodium azide, washed, and analyzed on an LSRII flow cytometer (BD 
Biosciences). Data were analyzed using FlowJo software. 
 
Statistical Analyses 
Unpaired Student’s t-tests were utilized to analyze normally distributed data. Mann-
Whitney U tests were used when data were not normally distributed. Two-way ANOVAs were 
used to compare paired data. Log-rank tests were used to analyze survival curves. p-values < 
0.05 were considered statistically significant. Hazard ratios with 95% confidence intervals were 
calculated for all survival curves. 
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Figure 3.1. Cerk knockdown sensitizes tumor cells to apoptosis in vitro following HER2/neu 
down-regulation 
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(A) Representative fluorescence images and (B) quantification of MTB/TAN primary tumor cell 
lines expressing empty vector, a control scrambled shRNA, shCerk1 or shCerk2 withdrawn from 
doxycycline 72 hr then stained for cleaved caspase-3 (red; Hoechst = blue). (C) Quantification of 
MTB/TAN primary tumor cell lines expressing empty vector, a control scrambled shRNA, shCerk1 
or shCerk2 withdrawn from doxycycline 72 hr then stained for Ki67. (D) Western blot of 
MTB/TAN primary tumor cell lines expressing empty vector, a control scrambled shRNA, or Cerk 
shRNA1 withdrawn from doxycycline 48 hr, blotted for cleaved PARP, quantified in (E), and 
cleaved caspase-3, quantified in (F). (G) Western blot of MTB/TAN primary tumor cell lines 
expressing empty vector, a control scrambled shRNA, or Cerk shRNA2 withdrawn from 
doxycycline 48 hr, blotted for cleaved PARP, quantified in (H), and cleaved caspase-3, quantified 
in (I). *p<0.05, **p<0.01, ***p<0.001.  
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Figure 3.2. Cerk is required for tumor cell survival following HER2/neu down-regulation  
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(A) qRT-PCR analysis of Cerk mRNA expression in Cerk knockdown tumor cell lines. (B) Schematic 
of competition assay and timing of doxycycline treatment and tumor harvest. (C) Percentage of 
eGFP-positive and mCherry-positive cells was determined at timepoints in (B) up to 28 days 
post-deinduction. Data represent mean ± SEM. (D) Representative fluorescence images of 
primary tumors, 96 hr deinduced tumors and residual lesions 28 days post-deinduction. (E) 
Percentage of eGFP-positive and mCherry-positive cells at timepoints in (B) in control cohort and 
(F) in a second shRNA cohort. *p<0.05, **p<0.01, ***p<0.001.  
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Figure 3.3. Cerk knockdown is not maintained in orthotopic recurrence assays 
 
(A) Recurrence-free survival of nude mice harboring primary orthotopic tumors from MTB/TAN 
primary tumor cell lines expressing empty vector, a control scrambled shRNA, shCerk1 or 
shCerk2 induced to regress by doxycycline withdrawal. (B) qRT-PCR analysis of Cerk mRNA 
expression in primary tumors formed from all cell lines in (A). (C) Recurrence-free survival of 
nude mice harboring MTB/TAN primary cell lines expressing empty vector, a control scrambled 
shRNA, shCerk1 or shCerk2 withdrawn from doxycycline 48 hr post-injection. (D) qRT-PCR 
analysis of Cerk mRNA expression in recurrent tumors formed from all cell lines in (C). 
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Figure 3.4. Characterization of FLIPi conditional shRNA expression system in vitro and 
MTB/TAN;Ubc-CreERT2 cell line 
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(A) Representative images of MTB/TAN;Ubc-CreERT2 cells transduced with FLIPi-shp53 construct 
treated with 4-OH-tamoxifen at indicated doses for 24 hr and (B) 48 hr. (C) Representative 
hematoxylin and eosin stained sections from primary MTB/TAN;Ubc-CreERT2 tumors. (D) 
Recurrence-free survival of nude mice harboring primary orthotopic tumors from 
MTB/TAN;Ubc-CreERT2 cells induced to regress by doxycycline withdrawal.  
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Figure 3.5. Characterization of FLIPi conditional shRNA expression system and MTB/TAN;Ubc-
CreERT2 cell line in vivo 
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Dissection images of primary orthotopic tumors generated from injection of MTB/TAN;Ubc-
CreERT2 FLIPi-shp53 cells, (A) untreated or treated with vehicle, (B) treated with tamoxifen for 1 
d, (C) treated with tamoxifen for 3 d, and (D) treated with tamoxifen for 5 d. 
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Figure 3.6. Conditional Cerk knockdown is not obtained using FLIPi system in vivo 
 
Recurrence-free survival of nude mice harboring primary orthotopic tumors from 
MTB/TAN;Ubc-CreERT2 primary tumor cell lines conditionally expressing FLIPi empty vector, a 
control scrambled shRNA, shCerk1 or shCerk2, (A) induced to recombine with 3 d tamoxifen 
treatment or (B) treated with vehicle, then induced to regress by doxycycline withdrawal. (C) 
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qRT-PCR analysis of Cerk mRNA expression in primary tumors, tumors withdrawn from 
doxycycline for 96 h, and recurrent tumors formed from all cohorts in (A) and (B).   
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Figure 3.7. MTB/TAN;Ubc-CreERT2 cells undergo efficient recombination upon treatment with 
tamoxifen but express low levels of shRNA 
 
(A) Flow cytometric analysis of MTB/TAN;Ubc-CreERT2 primary tumor cell lines before 
recombination (untreated) or following Cre-mediated recombination (treated with 4-OH-
tamoxifen). (B) qRT-PCR analysis of Cerk mRNA expression in MTB/TAN primary tumor cell lines 
constitutively expressing MLPHG empty vector, a control scrambled shRNA, shCerk1 or shCerk2, 
and MTB/TAN;Ubc-CreERT2 primary tumor cell lines transduced once (1x) or twice (2x) with FLIPi 
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empty vector, a control scrambled shRNA, shCerk1 or shCerk2 then induced to recombine with 
4-OH-tamoxifen treatment.   
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Figure 3.8. High dose NVP-231 treatment may synergize with lapatinib in HER2/neu–amplified 
human breast cancer cells 
 
BT474 and SKBR3 cells were treated with 100 nM lapatinib or DMSO and increasing doses of 
NVP-231 from 100 nM to 3 µM for 16 h (A)(D), 24 h (B)(E), or 48h (C)(F). Caspase activity values 
were measured with Caspase-Glo® 3/7 Assay System and normalized to viable cell number 
measured using the CellTiter-Glo® Luminescent Cell Viability Assay. 
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Figure 3.9. Growth curve cannot delineate role for Cerk in primary or recurrent tumor growth 
 
(A) qRT-PCR analysis of Cerk knockdown in primary (54074) and recurrent (42929 and 48316) 
MTB/TAN cell lines expressing empty vector, a control scrambled shRNA, shCerk1 or shCerk2. 
Growth curve demonstrating tumor volume over time for primary orthotopic tumors from (B) 
primary MTB/TAN cell lines (54074), (D) 42929 recurrent MTB/TAN cell lines and (F) 48316 
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recurrent MTB/TAN cell lines. Mean growth rates for (C) primary MTB/TAN cell lines (54074), (E) 
42929 recurrent MTB/TAN cell lines and (G) 48316 recurrent MTB/TAN cell lines. 
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CHAPTER 4: Summary and Future Directions 
Summary 
The ability of tumor cells to survive adjuvant or neoadjuvant therapy and persist in 
patients leads to breast cancer recurrence, and recurrence in turn is responsible for the majority 
of morbidity and mortality associated with breast cancer. Understanding pathways involved in 
tumor cell survival following therapy will provide insight into effective treatments to eliminate 
tumor cells during primary therapy thereby preventing breast cancer recurrence. In this thesis, 
we propose Ceramide Kinase as a novel target that is functionally involved in tumor cell survival 
following therapy. 
First we demonstrated that Cerk is spontaneously up-regulated in recurrent mammary 
tumors of inducible bitransgenic mouse models of breast cancer recurrence driven by four 
different oncogenes – HER2/neu, c-MYC, Wnt1 and Akt1. Having observed this up-regulation in 
vivo upon oncogene down-regulation, we then determined that Cerk is up-regulated in vitro in 
MTB/TAN cell lines following HER2/neu down-regulation, as well as in human HER2/neu-
amplified breast cancer cells following HER2/neu pathway inhibition with lapatinib. We also 
demonstrated that chemotherapeutic treatment with adriamycin leads to acute Cerk up-
regulation in mouse and human breast cancer cells. 
We then showed that Cerk up-regulation has the functional consequence of promoting 
tumor cell survival in vitro following HER2/neu down-regulation. Furthermore, Cerk promotes 
tumor cell survival in vivo acutely following HER2/neu down-regulation. As a result, Cerk 
promotes mammary tumor recurrence in vivo. 
Additionally, we interrogated human breast cancer patient datasets to determine 
whether CERK expression was predictive of outcome. We found that elevated CERK expression 
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was associated with an increased risk of recurrence in women with breast cancer. We also found 
that high CERK expression was associated with aggressive subtypes of breast cancer, including 
those with ER-negative status, PR-negative status, HER2-positive status, high tumor grade, and 
ErbB2 and basal-like tumors. We also found that the association between CERK expression and 
relapse-free survival in breast cancer patients was independent of the association between 
CERK expression and these aggressive tumor subsets. 
In loss of function studies, we sought to further our understanding of the potential 
usefulness of targeting Cerk in cancer. We found that Cerk knockdown sensitizes tumor cells to 
apoptosis in vitro following doxycycline withdrawal and HER2/neu down-regulation, as seen by 
increases in cleaved caspase-3 detected by immunofluorescence and Western blot. 
Furthermore, we found Cerk knockdown cells are strongly selected against following HER2/neu 
down-regulation in vivo. We hypothesize that the paracrine secretion of PGE2 may be involved 
in maintaining Cerk knockdown cells in primary tumors in the competition assay setting. This will 
have to be confirmed by experiments outlined in the next section (Future Directions). Secreted 
PGE2 may allow Cerk knockdown cells to persist in primary tumors in a setting where Cerk 
knockdown was previously determined to be lost. Cell-autonomous mechanisms may 
overwhelm the dependence on paracrine factors upon HER2/neu down-regulation, as Cerk 
knockdown cells were selected against very strongly within 96 hr despite the presence of control 
cells. 
We then wished to determine whether Cerk is required for tumor recurrence by 
performing Cerk knockdown recurrence assays. Due to difficulty maintaining knockdown using 
Cerk shRNAs, we were not able to answer this question using constitutive knockdown systems. 
We then turned to the FLIPi conditional shRNA expression system in an attempt to circumvent 
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selection events occurring against Cerk knockdown. We tested FLIPi in an MTB/TAN;Ubc-CreERT2 
cell line in vitro then in vivo, demonstrating that FLIPi was able to undergo efficient and tightly-
regulated recombination upon treatment with tamoxifen. 
Having optimized this system, we sought to address the initial question of whether Cerk 
was required for tumor recurrence by inducing recombination at deinduction, when doxycycline 
is withdrawn and HER2/neu is down-regulated. Unfortunately, we were not able to address the 
requirement for Cerk in tumor recurrence as no knockdown was detectable in any cohort 
irrespective of shRNA expression or treatment regimen. This system holds promise but will 
require further troubleshooting to answer the question of the requirement for Cerk in tumor 
recurrence. 
As genetic knockdown of Cerk proved technically challenging, we attempted to use the 
small molecule inhibitor of Cerk NVP-231 to test whether it would sensitize HER2/neu–amplified 
human breast cancer cells to lapatinib treatment. We found that high dose NVP-231 treatment 
may synergize with lapatinib, but as the doses were very high this effect may not be attributable 
solely to inhibition of Cerk.  
Lastly, having demonstrated a role for Cerk acutely upon oncogene down-regulation, we 
wanted to determine whether Cerk was required for actively proliferating primary and recurrent 
tumors. Although we saw no effect of Cerk knockdown on tumor growth rates, these results are 
inconclusive as Cerk knockdown was not shown to be maintained throughout the course of the 
experiment. 
The difficulty of maintaining Cerk knockdown in orthotopic recurrence assays in vivo 
may indicate a strong dependence of tumor cell lines on Cerk signaling, which in turn may 
indicate that Cerk has potential as a drug target in cancer cells. In aggregate, our findings 
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identify Cerk signaling as a pathway for cell survival in breast cancer cells that is sufficient to 
promote tumor recurrence. Additionally, we find that Cerk kinase activity is required for its 
effect promoting tumor cell survival. Moreover, we demonstrate a requirement for Cerk upon 
HER2/neu down-regulation as Cerk knockdown cells are subjected to strong negative selection 
in this context. We also find that high CERK expression defines a subset of human breast cancers 
with a high likelihood of relapse.  
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Future Directions 
Characterize Cerk protein expression in cell lines and tumors 
Although several antibodies have been synthesized against human CERK and are 
commercially available, two of which were predicted to have cross-reactivity against mouse, 
neither detected mouse Cerk in our hands (data not shown). As a result, we sought to generate 
a custom antibody for Cerk. Several attempts to generate purified full-length recombinant Cerk 
in bacteria and insect cells failed (data not shown). Consequently, we chose to use a peptide-
based approach to generate an antibody against Cerk. 
A C-terminal peptide identified by Open Biosystems (now Thermo-Fisher) was chosen 
for synthesis and immunization into two rabbits. Early bleeds (day 35, 56/58, 104, 145, 215 and 
264) from these rabbits have been tested for reactivity against mouse Cerk, and all bleeds from 
both rabbits detect overexpressed Cerk in cell lysates and immunoprecipitated HA-tagged Cerk. 
Purification was completed on bleeds from days 35, 56/58 and 104 from each rabbit 
independently, yielding two purified antibodies. Both antibodies also detected overexpressed 
Cerk in lysates and immunoprecipitated HA-tagged Cerk. It is unclear at this time whether the 
purified antibodies are capable of recognizing endogenous Cerk in cell and tumor lysates.  
Additional testing and characterization of these Cerk antibodies will be necessary before 
they can be of use. First, these antibodies need to be tested for immunoprecipitation of 
overexpressed, and subsequently endogenous, Cerk protein from cell lysates. The ability to 
immunoprecipitate Cerk may solve the issues of detection of endogenous protein by eliminating 
other proteins and concentrating Cerk. We have attempted immunoprecipitation with both 
purified Cerk antibodies and saw that they appear to be capable of immunoprecipitation. 
However, this has not been successfully repeated, so this experiment will require optimization.  
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Furthermore, later bleeds need to be tested for titer, and if their titer is higher than 
earlier bleeds then their purification will likely yield antibodies with higher avidity. Once a 
functional antibody has been optimized, then analysis of Cerk protein expression will be 
possible. Testing Cerk antibodies for immunofluorescence will also help provide key insights, as 
many questions about tumor heterogeneity as well as sub-cellular localization could be 
answered with immunofluorescence. 
First, Cerk expression patterns will need to be assessed by performing Western blots on 
tumor lysates from primary and recurrent tumors of MMTV-rtTA;TetO-HER2/neu, MMTV-
rtTA;TetO-MYC, MMTV-rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 mice. Additionally, 
immunofluorescence with this antibody will confirm changes in expression as well as help 
identify heterogeneity within tumors. This may identify regions of primary tumors with high 
levels of Cerk prior to oncogene down-regulation. 
Additionally, using the Cerk antibody, we will assess the changes of Cerk expression in 
response to HER2/neu down-regulation in vitro and in vivo to determine whether it follows 
mRNA up-regulation. We will also assess changes of Cerk protein expression in response to 
chemotherapy by treating MTB/TAN cell lines with adriamycin.  
 
Characterize ceramide-1-phosphate levels in cell lines and tumors 
An important question needing to be address is whether the product of Cerk, ceramide-
1-phosphate (C1P), is altered in proportion to Cerk protein levels. Specifically, when Cerk is 
overexpressed, C1P levels are expected to increase, and when Cerk is knocked down, C1P levels 
are expected to decrease. C1P is the only known product of Cerk, so the functional effect of Cerk 
is believed to be through its modulation of C1P and consequently ceramide levels. Confirming 
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this by assessing levels of C1P in cells and tumors where Cerk expression has been altered will 
help confirm or disprove that C1P is mediating the effects of Cerk on tumor cell survival and 
tumor recurrence. 
We addressed this question by liquid chromatography tandem mass spectrometry (LC-
MS/MS) in collaboration with the laboratory of Ian Blair (performed by Nate Snyder). We 
performed Folch lipid extractions of MTB/TAN cells with Cerk overexpression or Cerk 
knockdown. This was followed by liquid chromatography optimized for ceramides and tandem 
mass spectrometry on a TSQ Quantum Ultra™ Triple Stage Quadrupole Mass Spectrometer 
(Thermo Scientific), based on previously published protocols (226,227). Unfortunately, although 
we analyzed all species of C1P and ceramide between C12 and C22, we did not detect changes 
in C1P or ceramide that were consistent with levels of Cerk expression (assessed by mRNA).  
There are many possible explanations for the lack of changes observed, including the 
conditions in which cells were cultured. In normal culture conditions, the ceramide rheostat may 
be able to compensate for levels of Cerk and maintain physiological levels of C1P and ceramide. 
However, if the cells were placed in conditions of stress, such as serum deprivation, that are 
known to lead to ceramide accumulation, this may reveal a change in C1P to ceramide balance. 
These culture conditions may have to be optimized. 
The extraction protocols will also require optimization to minimize loss of ceramides 
thought to occur at several stages. Also, the LC-MS/MS protocols require optimization to 
account for the phosphorylation state of C1P and the chain lengths of C1P being detected. Once 
these steps have been optimized, this will allow for thorough characterization of C1P and 
ceramide levels in cell lines and tumors. We will perform LC-MS/MS on lipids extracted from 
primary and recurrent tumors of MMTV-rtTA;TetO-HER2/neu, MMTV-rtTA;TetO-MYC, MMTV-
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rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 mice to determine whether C1P and 
ceramide levels change as expected in correlation with Cerk protein levels. We will also assess 
the changes of C1P and ceramide in response to HER2/neu down-regulation in vitro and in vivo 
to determine whether they mirror predicted Cerk protein up-regulation. We will also measure 
changes in C1P and ceramide in response to chemotherapy in MTB/TAN cell lines treated with 
adriamycin. 
Importantly, optimization of LC-MS/MS will allow us to determine conclusively whether 
our G198D-Cerk mutant is truly kinase dead. A kinase assay will need to be performed in a cell-
free system to test for kinase activity of G198D-Cerk relative to wildtype Cerk. Also, this will 
allow us to address the possibility that G198D-Cerk may be dominant negative. This will be 
tested by detecting levels of C1P and Cerk in cells where G198D-Cerk is expressed and 
comparing to wildtype Cerk. If G198D-Cerk is dominant negative, it is expected that cells in 
which it is expressed will have lower levels of C1P than control cells. 
Together, these experiments will be very important in determining whether C1P is in 
fact mediating the effects of Cerk or whether an additional level of complexity may need to be 
investigated. If C1P is not found to mediate the effects of Cerk, this may indicate other roles for 
Cerk which would have to be elucidated. Cerk may have other substrates yet to be identified. 
Alternatively, Cerk may serve as a scaffolding protein or have other roles that have yet to be 
characterized. These options will have to be investigated to understand whether inhibition of 
kinase activity will be sufficient to prevent the pro-tumorigenic effects of Cerk, or whether other 
classes of inhibitors will be needed. 
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Determine the molecular mechanisms by which Cerk promotes tumor cell survival 
Once C1P can be confirmed or disproven to be mediating the effects of Cerk expression 
on tumor cell survival and tumor recurrence, the molecular mechanisms downstream will need 
to be elucidated. Attempts to identify signaling pathways that are differentially regulated in 
MTB/TAN cells with Cerk overexpression or Cerk knockdown following HER2/neu down-
regulation have not revealed any candidates (Figure 4.1). We investigated candidate pathways 
based on many previously published reports, including cPLA2, PI3K/AKT, NF-κB, and MAPK. 
Although these conditions demonstrated differential survival between MTB/TAN cells with Cerk 
overexpression, control and Cerk knockdown vectors, we did not see any alterations in signaling 
pathways, indicating the effect of Cerk on signaling pathways may be cell-type and context 
specific.  
Interestingly, cPLA2 protein levels and phosphorylation were found to be regulated by 
HER2/neu expression, as doxycycline withdrawal led to decreased phospho- and total-cPLA2 
levels, which has not been published (Figure 4.1A, B). Although this was not altered by levels of 
Cerk expression, this constitutes a novel finding that merits further investigation. 
In an attempt to interrogate potential pathways altered downstream of Cerk in a more 
unbiased way, we turned to phospho-protein arrays. As we had found that Cerk has an effect on 
cell survival, we identified phospho-protein arrays with many survival pathways, and chose 
Sigma-Aldrich’s Panorama® Antibody Microarray-XPRESS Profiler725. Unfortunately, these 
phospho-protein arrays only exist with antibodies with reactivity to human proteins, only a 
fraction of which cross-react with mouse proteins. We decided to transition to human cell lines 
to perform these phospho-protein arrays. We cloned seven shRNAs against CERK into the GIPZ 
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vector, packaged them in lentivirus, transduced BT474 cells and tested them for CERK 
knockdown. Three shRNAs yielded CERK knockdown of approximately 60% (Figure 4.2A). 
Prior to utilizing BT474 CERK knockdown cell lines for phospho-protein arrays, we tested 
them for candidate pathways following treatment with 100 nM lapatinib. No candidate 
pathways appeared altered in DMSO or lapatinib treated cells between control and CERK 
knockdown cells (Figure 4.2B-O). This indicates that either the levels of CERK knockdown 
obtained were insufficient to result in a change in survival pathways downstream or that the 
pathways tested may not regulate the effect of CERK in our system.  
Future experiments will need to address these two possibilities. The generation of 
BT474 cell lines with higher levels of CERK knockdown combined with the use of Sigma-Aldrich’s 
Panorama® Antibody Microarray-XPRESS Profiler725 will help identify pathways downstream of 
Cerk regulating its effect on cell survival in various contexts. Once candidate pathways have 
been identified by phospho-protein arrays, they will have to be validated by Western blot then 
confirmed by targeting those pathways to rescue apoptosis upon HER2/neu down-regulation.  
Characterizing signaling downstream of Cerk and C1P will help advance the 
understanding of the biology of tumors relying on this pathway and help identify the most 
relevant way of inhibiting escape mechanisms in tumor recurrence. 
 
Assess eicosanoid composition and involvement in tumor recurrence 
As we hypothesized that PGE2 secretion may be involved in maintaining Cerk knockdown 
tumor cells in the orthotopic competition assay, the question of eicosanoid composition and 
contribution to tumor progression must be addressed. Mass spectrometry methods have been 
developed to assess relative levels of many eicosanoids, particularly prostaglandins such as 
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PGE2, in tumors (228). Assessing changes in eicosanoid composition based on Cerk levels 
manipulated by overexpression, shRNA knockdown or germline knockout will help determine 
whether these changes may be mediating downstream effects of Cerk. We anticipate that Cerk 
overexpression will lead to increases in C1P levels and activation of cPLA2, which in turn will lead 
to increases in secreted PGE2. This would indicate that the balance of eicosanoids such as 
prostaglandins may be functionally involved in tumor recurrence. This will warrant further 
investigation by genetic manipulation of cPLA2. Pharmacological approaches to inhibiting 
eicosanoid synthesis could include administration of arachidonyl trifluoromethyl ketone 
(AACOCF3), an inhibitor of cPLA2 (229), or more clinically relevant, inhibitors of the 
cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. COX and LOX inhibitors are currently in 
clinical trials for their potential as chemopreventives. 
If Cerk is found to be an upstream regulator of eicosanoid synthesis in mammary 
tumors, it may offer a new way to target inflammatory signaling known to play a part in 
tumorigenesis and tumor progression in many cancers. Cerk’s role in inflammation has been 
identified, however, whether it has a functional role in cancer has not been addressed. These 
experiments would be instrumental in determining Cerk’s potential as a drug target. 
 
Determine whether Cerk is required for tumor recurrence 
Despite many attempts delineated in Chapter 3, the question of Cerk’s requirement in 
tumor recurrence still remains to be answered. This will need to be addressed either by 
optimizing the FLIPi system or by identifying a new system to express Cerk shRNAs conditionally. 
Upon recombination, the FLIPi vector generates a single transcript with the mCherry reporter 
followed by the shRNA of interest in a miR30 setting. This transcript is then spliced due to the 
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presence of splice donor and splice acceptor sites flanking the shRNA. This single transcript and 
processing required to release the shRNA may be at fault in creating low levels of shRNA 
transcript (Figure 3.7C, D). 
To address these issues, the FLIPi vector could be rearranged so that the fluorescent 
reporter is transcribed independently of the shRNA, hopefully leading to improved transcription 
of shRNA and circumventing the potential issues with processing. Alternatively, we could turn to 
other conditional expression systems such as pSico (230), and clone in a fluorescent reporter 
that would be expressed following recombination.  
With either approach, orthotopic recurrence assays will need to be performed to 
address the requirement for Cerk in tumor cell survival upon HER2/neu down-regulation and in 
tumor recurrence. Additionally, inducing recombination and expression of Cerk shRNAs at 
various points will allow elucidation of the role of Cerk at each stage of tumor progression. 
Additionally, the crossing of Cerk-/- mice with oncogene-induced cancer models needs to 
be performed. This will provide strong evidence for the role of Cerk in the context of 
tumorigenesis driven by specific oncogenes and tumor recurrence following oncogene down-
regulation. We propose crossing Cerk-/- mice with MMTV-rtTA;TetO-HER2/neu, MMTV-
rtTA;TetO-MYC, MMTV-rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 transgenic mice to 
determine whether loss of Cerk will delay tumor recurrence in these models. If Cerk knockout 
leads to delayed tumor recurrence in these mice, this will point to the possible utility of clinical 
intervention in this pathway to prevent or treat recurrent breast tumors. If, however, knockout 
of Cerk has no effect on tumor recurrence, compensatory pathways may be active in promoting 
tumor cell survival upon oncogene down-regulation and in tumor recurrence, which may 
indicate that Cerk would not be an ideal drug target for breast cancer patients.  
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Conclusions 
In aggregate, the proposed experiments will help to characterize CERK as a potential 
drug target in the context of breast cancer, particularly breast cancer refractory to targeted 
therapy. The ultimate hope would be to identify an inhibitor of CERK with good pharmacokinetic 
and pharmacodynamics profiles. We could then determine whether CERK inhibition in 
combination with chemotherapy and/or targeted therapy can overcome drug resistance in cell 
lines, mouse models of breast cancer, and ultimately in breast cancer patients.   
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Figure 4.1. Cerk knockdown or overexpression in MTB/TAN cell line withdrawn from 
doxycycline does not reveal differentially regulated signaling pathways 
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(A) Western blot of MTB/TAN primary tumor cell lines expressing empty vector or Cerk shRNA2 
withdrawn from doxycycline 72 hr, blotted for phospho- and total-cPLA2 quantified in (B), 
phospho- and total-p65 quantified in (C), phospho- and total-p44/42 MAPK quantified in (D), 
phospho- and total-Akt quantified in (E), and Bcl-xL quantified in (F). (G) Western blot of 
MTB/TAN primary tumor cell lines expressing Cerk, empty vector or Cerk shRNA2 withdrawn 
from doxycycline 72 hr, blotted for phospho- and total-cPLA2 quantified in (H), phospho- and 
total-p65 quantified in (I), phospho- and total-Akt quantified in (J), phospho- and total-p44/42 
MAPK quantified in (K), and Bcl-xL quantified in (L). 
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Figure 4.2. CERK knockdown in BT474 cell line treated with lapatinib does not reveal 
differentially regulated signaling pathways 
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(A) qRT-PCR analysis of CERK mRNA expression in CERK knockdown BT474 cell lines. (B) Western 
blot of BT474 cell lines expressing control shFF3 or shCerk1, shCerk2 or shCerk7 treated with 
DMSO or lapatinib 4 hr, blotted for phospho- and total-HER2 quantified in (C), phospho- and 
total-Akt quantified in (D), and Bcl-xL quantified in (E). (F) Western blot of BT474 cell lines 
expressing control shFF3 or shCerk1, shCerk2 or shCerk7 treated with DMSO or lapatinib 4 hr, 
blotted for phospho- and total-p65 quantified in (G), and phospho- and total-p44/42 MAPK 
quantified in (H). (I) Western blot of BT474 cell lines expressing control shFF3 or shCerk1, 
shCerk2 or shCerk7 treated with DMSO or lapatinib 4 hr, blotted for phospho- and total-JNK 
quantified in (J), and phospho- and total-Bcl-2 quantified in (K). (L) Western blot of BT474 cell 
lines expressing control shFF3 or shCerk1, shCerk2 or shCerk7 treated with DMSO or lapatinib 4 
hr, blotted for cleaved PARP (M), phospho- and total-GSK-3β quantified in (N), and total-IκBα 
quantified in (O). 
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